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INDUCTION OF MUCOSAL IMMUNE RESPONSES USING VIRUS-LIKE
PARTICLE BASED VACCINES

by

Zoe Hunter
BUS
PhD

ABSTRACT

Many viral structural proteins are capable of spontaneously self-assembling into
structures that resemble virus particles.

These structures, called virus-like particles

(VLPs), have multivalent, highly repetitive structures which are capable of inducing
robust and enduring immune responses, and, therefore, can serve as the basis for effective
vaccines.

VLPs can be used as stand-alone vaccines targeting the viruses from which

they are derived and also as platforms for presenting heterologous antigens; their ability
to evoke strong antibody responses against even poorly immunogenic targets makes them
an attractive model for future vaccine and drug delivery vehicle designs.

Our lab

developed display technologies that allow us to modify VLPs so they can present
essentially any potential target antigen on its surface. These technologies have led to the
development of several VLP-based vaccines that target molecules derived from microbial
and self-antigens. We have previously shown that when given intramuscularly, these
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vaccines consistently induce high-titer serum antibodies. Here we present data showing
that VLP-based vaccines are compatible with mucosal deliveries to both the genital and
respiratory tracts. Specifically, we displayed peptides from the HPV16 L2 coat protein
on the bacteriophage VLP platform PP7, and used a second bacteriophage VLP platform,
Q!, to target two domains of the cellular HIV coreceptor CCR5 involved in HIV binding.
Vaccines targeting both the viral and self-antigens were successful at inducing mucosal
and systemic immune responses, represented by the presence of IgA- and IgG-specific
antibodies. The induction of both mucosal and systemic immune responses presents a
particular advantage for preventing infection by pathogens transmitted at mucosal
surfaces.

Indeed, we determined that the L2 mucosal vaccine was successful at

preventing genital pseudoviral infection in a mouse model of HPV infection. As a
demonstration of the VLP’s ability to evoke strong antibody responses against a self - and
therefore weakly immunogenic - molecule, we also present data indicating that
immunization of macaques with our CCR5 vaccine results in the maintenance of
undetectable viral loads in some animals, indicating protection from infection following a
high-dose challenge with SIV. Our results provide a general method for the induction of
a broad, comprehensive immune response using VLPs as vaccine platforms.
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Chapter 1: Virus-like Particles as Platforms for Antigenic Display
1.1 Introduction to VLPs
Many viral structural proteins have the ability to spontaneously self-assemble into
virus-like particles (VLPs). VLPs are morphologically similar to and immunologically
indistinguishable from infectious virus, however their lack of a viral genome renders
them noninfectious. They are incredibly stable, and can easily be made upon overexpression of coat proteins from both enveloped and non-enveloped viruses. VLPs can be
produced from many viruses, including plant, avian and mammalian viruses, as well as
bacteriophage. The vast array of viruses available for VLP production and the inherent
biocompatibility of the resultant particles are just two of several traits that make VLPs
highly flexible materials for a multitude of in vivo applications, including targeted drug
delivery and vaccine development.
Below, I will describe the vaccine applications of VLPs. I will review how the
natural structure of VLPs can elicit strong immune responses and how the capsid can be
exploited as an antigen scaffold. Lastly, I will discuss how these features have led to a
new era in vaccine design.

1.2 Properties of VLPs that promote immune response
When a viral capsid protein is over-expressed, this protein can often self-assemble
into a VLP. VLPs are highly immunogenic, and this immunogenicity is related to
structural features of the VLPs. VLPs are particulate structures that contain a dense and
repetitive pattern of epitopes on their surfaces. Whereas monovalent, non-particulate
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antigens are often ignored by the immune system or induce weak responses, the
multivalent particulate nature of the VLP is specifically recognized as harmful by the
immune system. This is because particulate antigens are often of microbial origin, and
their display on microbial surfaces, such as bacterial pili and viruses, is often highly
multivalent.

In contrast, these particulate structures rarely occur amongst the self-

antigens expressed by vertebrate animals and normally exposed to the immune system.
Correspondingly, the immune system has developed mechanisms that allow it to
recognize and respond to these structural features.
1.2.1 Interactions with APCs
There are several determinants regulating the uptake of antigen by phagocytic
APCs including shape, charge, and hydrophobicity of the antigen complex, as well as the
size of the antigen itself. For example, the average size of viruses (and thus VLPs) is
between 20 and 100nm in diameter. Dendritic cells (DCs) have been shown to efficiently
and preferentially take up particles in this range (Fifis, Gamvrellis et al. 2004) while
macrophages, in contrast, take up larger antigens. Thus, it is likely that DCs are the
predominant type of APCs first encountering VLPs. Once bound to a DC, VLPs are
internalized, processed and presented on MHC class II molecules to activate T helper
cells. However, one advantage of the particulate nature of VLPs is that unlike nonparticulate exogenous antigens, VLPs can be trafficked to the cytosol for presentation by
MHC class I molecules. This is thought to occur in some DC lineages indirectly via
cross presentation, or directly by endosomal loading. To briefly review, antigens are
processed and presented to T cell pathways by major histocompatibility complex (MHC)
class I and class II molecules. In the endogenous processing pathway, peptides derived
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from cytosolic proteins are presented by MHC class I for recognition by CD8+ T cells,
while in the endosomal (or exogenous) processing pathway, peptides derived from
extracellular proteins are presented by MHC class II molecules for recruitment of CD4+
T cells. During cross-presentation, fragments of antigenic extracellular peptides from the
phagosome “cross over” and enter the MHC class I pathway following their initial uptake
by dendritic cells. The molecules are then transported to the cell surface for presentation
to CD8+ T cells (Cutler, Deepe et al. 2007). In this way, VLPs can trigger a CD8+ T
cell-mediated cytotoxic T lymphocyte (CTL) response in addition to the CD4+ T helper
response.
VLPs can also be designed or selected to enhance APC stimulation. For example,
VLPs derived from RNA viruses will have encapsidated single- or double-stranded RNA,
which are powerful agonists of toll-like receptors (TLRs) (Lee, Tucker et al. 2009).
Alternatively, there are several ways to

modify VLPs so as to increase

immunostimulation of APCs. These methods will be discussed in more detail below in
section 1.4.1. In addition to their interactions with professional APCs, VLPs have a
unique effect upon binding to a cognate B cell receptor (BCR).
1.2.2 Interactions with B cells
Just as the magnitude of an immune response following an APCs’ uptake of
antigen depends on several factors, so does the magnitude of response following the
binding of antigen to its BCR. Ultimately, antibody production relies upon the strength
of this interaction at the surface of a naïve B cell. The unique spacing of viral epitopes
on the VLP surface in a dense, repetitive and multivalent array can enhance the strength
of this interaction. When multiple BCRs are engaged, or “cross-linked”, it promotes the
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formation of stable lipid rafts, which can act as arenas for enhanced signaling to the B
cell (Thyagarajan, Arunkumar et al. 2003).

Examples of such signaling include

upregulation of costimulatory molecules (such as CD80, CD86, CD40L and MHC class
II), and stimulation of B cell proliferation, migration and maturation.

Downstream

effects of these signaling events include engagement of T helper cells and subsequent Ig
class switching, affinity maturation, and production of memory B cells.

Thus,

immunization with multivalent antigens, such as VLPs, results in quantitatively stronger
antibody responses than immunization with monovalent or paucivalent antigens.

1.3 VLP Vaccines
Virus-like particles can be used directly as vaccines against the virus from which
they were derived. Their morphological similarity to infectious virus and inability to
replicate make them naturally potent and safe immunogens, and their particulate nature
makes them ideal for fast and easy purifications. As I will describe below, the ability of
VLPs ability to display heterologous antigens allows them also to serve as the basis for
vaccines against antigens that are typically weakly immunogenic in their native context.
Viral vaccines have traditionally been based on inactivated or attenuated viruses,
but there are several advantages to the VLP-based vaccines on the market today. Like
VLPs themselves, attenuated viruses are highly immunogenic and can activate both
humoral and cell-mediated responses upon immunization. However, attenuated vaccines
do not have the inherent safety proffered by VLPs. Viral reversion can occur, leading to
the risk of a vaccine-related outbreak (Roberts 2007), and they have also been shown to
be dangerous in pregnant and immunocompromised individuals. The manufacturing and
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distribution of inactivated viral vaccines also raises safety concerns. Large volumes of
virulent pathogens must be handled when manufacturing the vaccine, and there is the risk
that the virus may be incompletely inactivated. Perhaps one of the most attractive
advantages to developing a VLP-based vaccine is its readiness to market. Unlike the
inactivated and attenuated vaccine methods, which require the production of large
quantities of virus reliant on replication of a parent strain, VLPs can be produced using
recombinant technologies.

For example, human-derived VLPs like HPV can be

generated in yeast, bacteria, plant, and baculovirus/insect cell expression systems as well
as in their natural mammalian cell culture system (Kirnbauer, Booy et al. 1992; Hofmann,
Cook et al. 1995; Nardelli-Haefliger, Roden et al. 1997; Warzecha, Mason et al. 2003;
Buck, Pastrana et al. 2004). Examples of the wide of variety of VLP-based vaccines in
development are shown in Table 1.
In addition to inactivated and attenuated viral vaccines, which are based on whole
virus preparations, there are also subunit vaccines, which are based on isolated viral
proteins. Because they rely on the production of individual viral components, subunit
vaccines are also manufactured using recombinant technologies. However, vaccines
based on individual proteins are typically less effective than those based on whole virus.
The isolated antigen does not always reflect the native structure of the protein, nor are the
antibody responses always specific for physiologically relevant epitopes. As a
consequence, administration of these vaccines often requires use of strong adjuvants, as
well as large and frequent doses of the antigen. In contrast, VLP-based vaccines are
strongly immunogenic, often reducing or eliminating the need for exogenous adjuvants.
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Table 1.1. Selected virus-like particles used as vaccine platforms
Conjugation
method(s)

Target epitopes

Refs

Hepadnavirus core Ag
(HBV, WHV, DHV)

Genetic and
chemical

(B cell or CTL) Malaria, Influenza, FMDV, HCV,
Hantavirus and others

(Milich, Peterson et

HPV

Genetic and
chemical

(B cell) HIV, Influenza
(CTL) HPV E2 & E7, P1A tumor antigen, HIV

Parvovirus
(PPV, B19)

Genetic

(B cell) Dengue Virus, Anthrax
(CTL) LCMV

MPyV

Genetic

(CTL) Her2/Neu (Breast Cancer)

VLP type

Animal Viruses
al. 1995; Pumpens
and Grens 2001)
(Slupetzky, ShaftiKeramat et al. 2001;
Ionescu, Przysiecki
et al. 2006)
(Greenstone, Nieland
et al. 1998; Peng,
Frazer et al. 1998;
Nieland, Da Silva et
al. 1999; Liu, Liu et
al. 2000)
(Amexis and Young
2006; Ogasawara,
Amexis et al. 2006)
(Sedlik, Saron et al.
1997)

(Tegerstedt,
Lindencrona et al.
2005)

Plant Viruses
CPMV

Genetic and
chemical

(B cell) HIV, rhinovirus, P. aeruginosa, MEV

PVX

Genetic

HIV

TMV

Genetic and
chemical

(B cell) HPV L2
(CTL) Mouse melanoma-associated peptides

Qß

Chemical

(B cell) Nicotine, Der p1 allergen
(CTL) LCMV

MS2

Genetic

(B cell) HIV

Genetic

(B cell) HIV, Influenza
(CTL) HIV

(Porta, Spall et al.
1996; Dalsgaard,
Uttenthal et al. 1997;
Brennan, Gilleland et
al. 1999)
(Marusic, Rizza et al.
2001)
(Smith, Lindbo et al.
2006)
(McCormick, Corbo
et al. 2006)

Bacteriophage
(Maurer, Jennings et
al. 2005; Kundig,
Senti et al. 2006)
(Storni, Ruedl et al.
2004)
(Mastico, Talbot et
al. 1993)

Other particles
Yeast Ty Particles

(Adams, Burns et al.
1994)

1.3.1 Commercial VLP-based vaccines
There are currently clinically approved VLP-based vaccines against two viruses:
hepatitis B virus (HBV) and human papillomavirus (HPV). These viruses are known to
cause cancer (liver and cervical cancer, respectively) in humans. Vaccines against these
viruses protect against infection by generating neutralizing antibodies.

The HBV

vaccines Recombivax (Merck & Co., Inc.) and Energix (GlaxoSmithKline [GSK]), both
released in 1986, were the first commercial vaccines generated using recombinant DNA
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technology (Scolnick, McLean et al. 1984). The VLPs, which are approximately 22nm in
diameter, are produced in yeast and have the hepatitis B surface antigen (HBsAg)
incorporated into yeast lipid membrane particles (McAleer, Buynak et al. 1992).
Two commercial vaccines exist against HPV, Gardasil (Merck) and Cervarix
(GSK). Both are composed of VLPs assembled from the HPV major capsid protein, L1
(Lowy and Schiller 2006). Cervarix, released in 2007, is composed of HPV type 16 and
18 VLPs that are generated in L1 recombinant baculovirus-infected insect cells. (HPV
types 16 and 18 are found in approximately 70% of cervical cancers.) In contrast to
Cervarix, the L1 VLPs for the Gardasil vaccine are produced in yeast. Gardasil, which
was released in 2006, targets four HPV types: 16, 18, 6 and 11. Types 6 and 11 cause
about 90% of external genital warts.
The HBV and HPV vaccines have excellent safety profiles, and have been shown
to induce long-lasting antibodies. In the case of HPV vaccines, which are administered
three times over six months, virtually 100% seroconversion has been induced, and titers
have remained high throughout the six years since clinical trials first began (Munoz,
Kjaer et al. ; Koutsky, Ault et al. 2002; Paavonen, Naud et al. 2009). The antibodies
generated following immunization with the HBV vaccines have been detected in
vaccinees up to 20 years after vaccination (Poovorawan, Chongsrisawat et al.). Most
importantly, rates of acute hepatitis have decreased dramatically where universal
vaccination programs have been enforced (Zanetti, Van Damme et al. 2008). In addition
to these clinically approved VLP-based vaccines, there are several other vaccines in
development and clinical trial that target a variety of heterologous molecules, including
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pathogens, chemical agents, and even self antigens. These are discussed in sections 1.5
and 1.6 below.
1.3.2 Adjuvants
One of the major advantages of the VLP platform in vaccine design is the limited
need for adjuvants.

However, their structure and flexibility also provide a unique

opportunity to modify the particle platform to incorporate adjuvants that will specifically
stimulate select populations of cells. Structurally, VLPs are composed of viral coat
proteins that essentially self-assemble into a hollow particle shell. This shell can then be
modified

to

encapsidate

immunostimulatory

substances.

For

example,

CpG

oligonucleotides can be loaded into VLPs to specifically act as TLR9 agonists, which will
then activate CD8+ T cells (Storni, Ruedl et al. 2004). As was discussed briefly above,
antigen presenting cells can be specifically activated by incorporating single- or doublestranded RNA into the particle, which will act as an agonist for TLR3 and TLR7/8,
respectively. Alternatively, adjuvant molecules can be linked to the particle surface,
much like target antigens.

This has been previously described using SIV particles

chemically linked to cholera toxin B, which is a strong mucosal adjuvant (Kang, Yao et
al. 2003). The ability of virtually any VLP to package its own adjuvant is yet another
advantage towards its applicability and safety.

1.4 VLPs as scaffolds for antigenic display
As was previously mentioned, VLPs can be derived from any number of viruses
and provide strong signals to both the cellular and humoral arms of the immune system.
Hence, the VLP provides a flexible platform upon which to display practically any
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antigen. Indeed, displaying antigens on the VLP surface has been used to target a diverse
number of molecules, particularly those that are poorly immunogenic in their native
context.

In order to exploit the immunogenic properties of the VLP platform, the

displayed molecule must be presented in the same format: a repetitive, multivalent
structure.
There are several means by which to achieve arrangement of antigens in this highly
dense array on the particle surface. Choosing a method for conjugating a target antigen
to the VLP platform can depend on several variables, particularly the surface chemistry
of the VLP, the antigen in question, and the type of immune response (CTL, humoral)
you want to elicit. Both chemical and genetic approaches, and the advantages and
disadvantages of each, are discussed below.
1.4.1 Chemical conjugation
One strategy for presenting target antigens in a highly multivalent fashion on the
surface of VLPs is to use bridging molecules to chemically link them to the surface of a
preformed VLP. There are several advantages to using a chemical conjugation approach.
Notably, target antigens are not limited to proteins; glycans and other small haptens have
been attached to VLPs (Raja, Wang et al. 2003). Also, chemical conjugation can be used
to attach both peptides and full-length proteins to the viral surface, making for flexibility
in vaccine design. While having a linear target peptide as a display epitope can cater to
precise targeting of known epitopes critical for vaccine success, a larger protein target
can be used to induce a wide range of antibodies capable of recognizing both linear and
conformational epitopes on the target molecule. Regardless of the nature of the target
antigen, using a chemical conjugation approach requires an understanding of the surface
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chemistry of the VLP so that linkage-compatible moieties can be identified on both it and
the target.
A number of different strategies have been used to display target antigens on the
surface of preformed VLPs.

For example, the incredible avidity of the biotin and

streptavidin interaction can be exploited by using streptavidin (SA) as a bridging
molecule between biotinylated antigens and their VLP platform. Briefly, a preassembled
SA tetramer can be reacted with biotinylated target antigens at a molar ratio that will
leave one SA binding site unoccupied. The free site on the SA tetramer-antigen complex
can then be exposed to and reacted with biotinylated VLPs, with the SA acting as a
bridge between the VLP and the display antigens. Our lab has previously used this
method with biotinylated papillomavirus VLPs to display a diverse number of
biotinylated antigens on its surface (Chackerian, Rangel et al. 2006). The streptavidin
bridge also allows for conjugation of larger proteins, such as hen egg lysozyme, to the
particle surface (Chackerian, Durfee et al. 2008).
A second strategy for chemical conjugation is to use chemical crosslinkers to
display target antigens on the VLP surface. The bifunctional cross-linker, SMPH, has
been used extensively in our laboratory to conjugate cysteine-containing antigens to VLP
surfaces rich in exposed lysines. This is made possible by the amine- and sulfhydrylreactive “arms” of SMPH. If a viral coat protein is known to have lysine residues
exposed on its surface, the target antigen can be engineered, synthesized, or modified to
contain cysteine residues on its terminus (provided the antigen is peptide-based) and the
two can be chemically linked via SMPH (Figure 1.1).
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One consideration when using SMPH is the size of the target peptide. Smaller
peptides are more likely to achieve a high-density display on the particle surface, while
larger targets will often result in a reduced conjugation efficiency. For example, we have
previously shown that the Q! bacteriophage VLP can support up to 240 molecules of a
12 amino acid peptide on its surface; in contrast, only 18 copies of a 34kD IL-17
homodimer were able to be linked to its surface (Jegerlehner, Storni et al. 2002;
Chackerian, Rangel et al. 2006; Rohn, Jennings et al. 2006). While size can affect the
density at which a molecule can be displayed, chemical conjugation is the more
permissive technique for conjugating targets of diverse size and molecular structure.

Figure 1.1: Chemical Conjugation Method of Antigenic Display

Figure 1.1. An example of the chemical conjugation method. A naked VLP with surface
lysines is treated with a chemical crosslinker such as SMPH or biotin, creating a
“modified VLP.” Target antigens containing a free sulfhydryl, such as the cyclic ECL2
peptide (shown in pink) can then be attached, resulting in a chemically conjugated VLP
presenting the target antigen in a repetitive fashion on its surface.
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1.4.2 Recombinant VLPs/Genetic Insertion
Another method for displaying heterologous epitopes on the VLP surface is
genetic insertion. This method generates a chimeric particle in which a target sequence is
successfully incorporated into the viral structural protein. While there are often more
technical challenges and a finite range of epitope sizes permitted, the major advantage of
this approach is that the target antigen will be displayed in a consistent conformation and
density on the particle surface. (Figure 1.2) In order for an insertion site to tolerate
peptide incorporation, the insertion must not interfere with coat protein folding or VLP
assembly. Furthermore, the location of the site must result in the peptide being on
displayed on the exposed surface of the particle. Peptide length, hydrophobicity, charge,
and structure all need to be taken into consideration when designing a chimeric or
recombinant VLP. These barriers have limited the applicability of the genetic approach
for peptide display on VLPs.
Numerous technologies have been developed to increase the likelihood of success
with the genetic display system.

The vast number of viruses amenable to particle

formation has greatly spurred these advances, which utilize unique features of insect,
plant, bacteriophage, and animal viral platforms to best adapt them for genetic insertion.
In our laboratory, we have used a technique in which short peptides can be inserted into
the modified coat proteins of two related RNA bacteriophage, MS2 and PP7. The major
advantage of this approach is that it allows for near universal display of short peptides on
these VLPs.
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Figure 1.2: Genetic Insertion Method of Antigenic Display

Figure 1.2. Using a genetic insertion model of antigenic display, short peptides can be
inserted into modified coat proteins (for example the RNA bacteriophage MS2), and
upon translation and assembly, displayed uniformly on the VLP surface (top panel).
One disadvantage of this method is as peptide size increases, the VLPs tolerance for
insertion (and therefore successful assembly) decreases. An example of this trend is
depicted in the bottom panel.

1.5 VLP-based vaccines currently in clinical trial and preclinical development
As was shown in Table 1, there are several VLP-based vaccines that utilize a
variety of VLP types and conjugation methods to target a diverse panel of antigens. The
hepatitis B core antigen has been used extensively to form VLPs for antigenic display, as
its structure has several sites that are well-suited for genetic insertion. One vaccine,
ACAM-FLU-A, was generated using recombinant techniques and underwent a phase I
clinical trial.

ACAM-FLU-A targets the influenza A M2 protein, which is highly

conserved amongst influenza A strains. The company Acambis, who developed the
vaccine, has not yet reported the results from the human tests, but has indicated that 90%
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of volunteers were able to produce measurable antibodies against M2. Previous studies
showed protection in animals (Neirynck, Deroo et al. 1999).
A second VLP-based vaccine in clinical trials targets nicotine in an effort to
create an anti-smoking vaccine.

By generating antibodies against the chemical, the

amount and rate of nicotine entering the brain will be reduced, potentially contributing to
a permanent cessation of smoking. Nicotine was conjugated to the RNA bacteriophage
Q! using chemical conjugation methods; following immunization it was reported that
nicotine-specific IgG responses were generated. The vaccine was tested for efficacy in
227 smokers in a phase II clinical trial. Approximately one-third of the smoking
population that received the vaccine was able to continuously abstain from smoking, a
proportion nearly twice that of the placebo group (Maurer, Jennings et al. 2005; Cornuz,
Zwahlen et al. 2008).
As was previously mentioned, the HBV VLP has been used extensively as a
scaffold for other target epitopes. In addition to the influenza vaccine, these include but
are not limited to malaria, hantavirus, and hepatitis C virus.

Candidate VLP-based

vaccines have also been generated for Rotavirus, Norwalk virus, hepatitis E virus, and
Parvovirus.

These involve formation of a naked, icosahedral VLP; other candidate

vaccines involving lipid-envelope containing VLPs are also in development against HIV,
hepatitis C virus, and SARS coronavirus. In addition to these infectious pathogens, many
VLP-based vaccines currently in development are targeting self-antigens (Roy and Noad
2009)
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1.6 Targeting self antigens
While the traditional targets of vaccines are infectious pathogens, the highly
immunogenic nature of the VLP, compounded with its ability to display multiple types
and sizes of antigen, has led to an increased interest in exploiting the VLP to induce
antibody responses against self. Subverting the immune system in order to purposely
elicit an anti-self response is desirable in cases where self-molecules are involved in
chronic diseases processes, such as cancer and autoimmune disease. Several therapeutics
have succeeded in using monoclonal antibodies (mAb) to this end, however a vaccinebased approach overcomes the need for frequent administration, thereby reducing cost,
and reduces the likelihood of an inactivating, anti-antibody response.
The prevailing thought is that the mechanisms of B cell tolerance prohibit
induction of antibody against self; however, the immune system often fails in this matter,
generating up to 50% autoreactive cells in a mature B cell population (Wardemann,
Yurasov et al. 2003). In actuality, there are two primary obstacles to producing longlived, high-titer antibodies against self. First, potentially self-reactive naïve B cells
typically downregulate the expression of their B cell receptor. Because of this lower
expression, these B cells are only efficiently activated by highly multivalent antigens
(Chackerian, Durfee et al. 2008). Secondly, B cells require help from CD4+ T cells in
order to undergo class switching, affinity maturation, and generation of memory cells.
The mechanisms of both peripheral and central T cell tolerance are more stringent than
those in place for B cell tolerance. T cell tolerance results in complete ignorance of the
auto-reactive B cell, serving to efficiently prevent its proliferation and subsequent
production of potentially harmful IgG auto-antibodies.
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Many prior strategies in vaccine design aimed at generating long-lasting anti-self
IgG have involved inclusion of foreign T helper epitopes with self-antigens; this is
usually accomplished via chemical or genetic approaches, and in the presence of strong
adjuvants. While these vaccines have been somewhat successful, a high dose of antigen
is often required, yet the IgG titers remain low and tend to diminish rapidly. Data from
our laboratory has shown that display of self-antigens on VLPs, which provides antigen
multivalency and the presence of foreign T helper epitopes, can efficiently induce
antibodies against self (Chackerian, Durfee et al., 2008). VLP display makes self antigens
as immunogenic as foreign antigens presented in the same context (Chackerian, Lowy et
al. 2001). Several VLP-based vaccines targeting self are currently in clinical trial: these
are shown in more detail in TABLE 1.2

Table 1.2: Selected VLP-based vaccines targeting self-antigens
Disease
Arthritis, encephalomyelitis,
and autoimmune myocarditis

Target Antigen
IL-17

Status
Pre-clinical

Hypertension

Angiotensin II

Phase I/II trials (Cytos)

Alzheimer’s Disease

Aß

Phase I/II trials (Novartis/Cytos)

Rheumatoid arthritis, psoriasis,
and Crohn’s Disease

TNF-"

Pre-clinical

HIV infection

CCR5

Pre-clinical

Osteoporesis

TRANCE/RANKL

Pre-clinical

(Chackerian,
Lowy et al. 1999;
Chackerian,
Briglio et al.
2004)
(Spohn, Schwarz
et al. 2005)

Obesity

Ghrelin

Phase I/II trials (Cytos)

(Dyer, Renner et
al. 2006)

Epithelial Cancers

MUC1

Pre-clinical

(Gathuru, Koide
et al. 2005)

IL: Interleukin; Aß: Amyloid-beta peptide; HIV: Human Immunodeficiency Virus
CCR5: chemokine (C-C motif) receptor 5; TNF-a: Tumor necrosis factor alpha
TRANCE/RANKL: Tumor necrosis factor-related activation-induced cytokine, also
known as receptor activator of nuclear factor-kappa B ligand.
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Refs.
(Rohn, Jennings
et al. 2006;
Sonderegger,
Rohn et al. 2006)
(Ambuhl, Tissot
et al. 2007)
(Li, Cao et al.
2004; Zamora,
Handisurya et al.
2006)
(Chackerian,
Lowy et al. 2001)

Chapter 2: Delineation of Thesis
2.1 Rationale/Statement of the problem
HIV affects an estimated 33 million people worldwide, with approximately 3
million individuals newly infected with the virus in 2008. The majority of these
infections occur in impoverished regions of the world, particularly sub-saharan Africa
(UNAIDS/WHO, 2009). Thus, the need for global containment of the HIV pandemic is
acute, and the combined goal of prevention and treatment is a focal point in the field of
HIV research.
Although the emergence of highly active anti-retroviral therapies (HAART) over
the past two decades has vastly improved treatment of HIV infection, there is an ongoing
need for prevention. The expense and adverse side effects associated with antiviral drugs
argue for further investment in novel vaccine-based therapies, which have the potential
for wider spread distribution at lower costs. Yet despite numerous efforts, an AIDS
vaccine remains elusive. The promising STEP trial of 2004 tested a “T cell only” vaccine
using recombinant adenovirus to express HIV proteins. However, the vaccine failed to
provide protection, and was stopped in 2007 at phase IIb after some participants showed
enhanced acquisition of HIV-1 infection (Steinbrook 2007). The specific reasons for this
occurrence are unknown, though it was shown that pre-existing immunity to the Ad5
vector was an independent risk factor in the increased rate of HIV acquisition among
vaccine recipients. Several hypotheses exist to explain the increased susceptibility to
HIV-1 infection, including: 1) that receipt of the vaccine boosted adenovirus-specific T
cells, which resulted in higher numbers of activated target at cells at mucosal sites
following high risk sexual behavior, 2) that prior adenovirus immunity skewed the
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immune response to the vector and reduced the innate immune response to HIV-1
infection, and 3) that pre-existing immunity resulted in the production of “enhancing”
antibodies that increased susceptibility to infection (Corey, McElrath et al. 2009). Of
course, additional hypotheses, or a combination of all three hypotheses is also possible;
alternatively, it is still unclear whether the increased acquisition in Ad5 seropositive
vaccines actually has an underlying biologic mechanism. Indeed, at least one other group
has shown experimentally that seropositive Ad5 status does not predict a significant
increase in Ad5-specific CD4+ T cell frequency prior to or following vaccination
(Hutnick, Carnathan et al. 2009).
Ultimately, it seems that sufficient concentrations of long-lasting, protective
antibodies will have to be present at the time and site of transmission for successful
elimination of HIV-infected cells. Inducing and maintaining high levels of antibody
against HIV is difficult due to many factors, including but not limited to the vast
sequence diversity of the various subtypes, the structure of the virus envelope, and the
mechanisms of immune evasion the virus employs.

2.2 CCR5
CCR5 is a cellular protein critically involved in HIV acquisition and replication.
It is expressed on a number of immune cells, including but not limited to CD4+ T cells,
macrophages and dendritic cells. It belongs to the chemokine receptor family, which are
cell surface receptors for chemokines that act to promote cellular migration by
chemotaxis. The natural ligands of CCR5 are MIP-1", MIP-1!, and RANTES; these
chemokines can bind, signal through, and promote internalization of CCR5. Structurally,
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CCR5 is a G-protein coupled receptor (GPCR), characterized by seven membranespanning domains, three extracellular loops and four intracellular loops (Figure 2.1).

Figure 2.1: CCR5 Structure

The 3-dimensional structure of CCR5 is thought to be similar to that of another GPCR,
rhodopsin, with the TM domains arranged in a cluster. To illustrate this, we have shown
on Figure 2.1 where the third extracellular loop (ECL3) connects to the N-terminal
extracellular region (EC1, or N-term). The EC1 and ECL2 regions (shown in blue and
pink, respectively) have been implicated in HIV entry, and are discussed in further detail
in Chapter 3.
CCR5 has a number of proposed functions in vivo, including priming of adaptive
immune responses, distribution of effector cells to microbial infection sites, and
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amplification of inflammation. The ability of one chemokine receptor to bind several
ligands is thought to contribute to the overall effectiveness of host response to microbial
challenges; it is also one reason that targeted suppression of a chemokine receptor can be
tolerated, as many chemokines also bind multiple receptors to carry out overlapping
functions. Targeting a stable self-protein such as CCR5, rather than HIV itself, is one
strategy to overcome the problem of viral mutation.
2.2.1

CCR5 as therapeutic target

A major barrier to developing an HIV vaccine is the genetic variability of the
virus.

Instead of targeting the virus itself, one strategy is to develop methods for

targeting cellular proteins that are critically important during HIV infection. CCR5,
which is utilized by HIV as an entry co-receptor, is a promising candidate for several
reasons (Dean, Carrington et al. 1996; Liu, Paxton et al. 1996; Samson, Libert et al.
1996). Of the coreceptors available to HIV during entry, CCR5 is considered the most
physiologically important. Viruses that use CCR5 as a co-receptor are termed CCR5tropic and predominate throughout the course of HIV infection, thereby making CCR5 an
important target for vaccine design.

In the early stages of infection, the virus strains

isolated are exclusively CCR5-tropic, suggesting a possible selective advantage for these
viruses during transmission or early onset of disease (Li, Juarez et al. 1999). In addition
to binding its primary receptor CD4, HIV needs to bind to a second chemokine
coreceptor, either CXCR4 or CCR5, to gain entry into host cells. Briefly,initial binding
of HIV envelope glycoproteins to CD4 results in a conformational change in these
proteins, exposing binding sites that permit the coreceptor to bind the virion. Once HIV
is bound both to CD4 and the coreceptor, a second conformational change takes place,
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allowing for fusion of the HIV virion to the cell surface and subsequent entry of viral
contents (Lederman, Penn-Nicholson et al. 2006).
Shortly after the role of CCR5 in viral acquisition was determined, a deletion
mutation of 32 base pairs was identified in the coding region of the CCR5 gene.
Individuals harboring a homozygous mutation of the CCR5 allele (termed Delta-32) were
resistant to HIV infection, while heterozygous individuals progressed slowly from HIV
infection to AIDS (Samson, Libert et al. 1996; Winkler, Modi et al. 1998). Figure 2.2
shows how the Delta-32 mutation prohibits viral entry by truncating the CCR5 receptor.
The role of CCR5 in HIV acquisition has prompted numerous investigators to use CCR5
for drug development. These drugs target CCR5 by blocking viral entry either through
small interfering RNAs, monoclonal antibodies, or small molecule inhibitors, and one
small molecule inhibitor, Maraviroc, is clinically approved (Baba, Nishimura et al. 1999;
Trkola, Ketas et al. 2001; Barassi, Soprana et al. 2005).

Figure 2.2: CCR5 structure resulting from the Delta-32 mutation

Figure 2.2
The #32 mutation results
in the loss of three
transmembrane domains,
two of the three outer
loops,
and
the
intracellular
signaling
domain. The defective
CCR5 molecule is not
expressed on the cell
surface.
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While a therapeutic approach is valid, there are also advantages to using CCR5 as
a vaccine target. Unlike most viral vaccine targets, which mutate rapidly during the
course of infection, CCR5 is a cellular protein and therefore genetically stable.
Targeting the receptor itself - either by limiting its expression on the cell surface or by
blocking virus-receptor interactions - should have substantial effects on viral
pathogenesis.

More importantly, a vaccine against CCR5 has the potential for

prophylactic use.

2.3 Mucosal immunity may be critical for attenuating viral acquisition
An important consideration in HIV-1 vaccine development is the induction of a
mucosal immune response in addition to a systemic response.

The conventional

parenteral approaches, while successful at inducing a systemic response, do not address
the fact that most infectious pathogens (including HIV) initiate infection at a mucosal
surface. Thus, induction of mucosal responses could provide better protection at the site
of infection.

Establishment of HIV-1 infection depends largely on the genital and

gastrointestinal mucosas, which respectively play important roles in transmission, as well
as viral replication and amplification (Veazey and Lackner 2003). Mucosal antibodies,
usually of the IgA subtype, are consequently often found at these sites. Secretory IgA
mediates mucosal defense through mechanisms inclusive of, but not limited to, inhibition
of inflammatory responses, virus neutralization, and antigen elimination, highlighting the
important role of mucosal immunity in combating infection (Dean, Carrington et al.
1996; Holmgren and Czerkinsky 2005).
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Inducing a strong mucosal response may be particularly important when targeting
CCR5. While HIV can use either CCR5 or CXCR4 as a coreceptor during viral entry,
mucosal transmission is almost exclusively restricted to viruses that use CCR5 (Margolis
and Shattock 2006). Moreover, large numbers of CD4+ T cells in the gastrointestinalassociated lymphoid tissue (GALT) are rapidly depleted during HIV infection, which is
likely due to the high levels of CCR5- expressing cells in the GALT as compared to cells
in other locations (Brenchley, Schacker et al. 2004).
The most important determinant for the successful initiation of a broad mucosal
response may be the route of vaccine administration. Indeed, the compartmentalization of
the mucosal immune system has led to several options for mucosal immunization that are
catered to target tissues (i.e. oral, nasal, and vaginal immunizations for gastric,
pulmonary, and genital responses, respectively). Furthermore, mucosal immunization can
in turn confer systemic immunity, while the reverse is not always attainable. The use of
parenterally administered vaccines is often limited in developing countries by high costs
and safety considerations (Levine 2003). In contrast, a non-invasive delivery directly to
the mucosa would offer a safe and cost-effective approach to establishment of mucosal
immunity, with the ultimate goal of global containment of HIV infection through
prophylactic and therapeutic means.

2.4 Hypothesis
My hypothesis is that use of a VLP vaccine platform will be compatible with
aerosol delivery to mucosal tissues and result in enhanced mucosal immune response
against self- and non-self antigens, specifically the HIV coreceptor CCR5 and the HPV16
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L2 capsid protein, respectively. (An extensive background and rationale for targeting L2
is provided in Chapter 4, as the primary focus of this work is on vaccines targeting
CCR5.) Mucosal delivery of a VLP-based vaccine will protect against viral infection in a
relevant animal model.

2.5 Specific Aims
Aim 1. Characterize the immunogenicity of VLP-based CCR5 vaccines. We will
construct a bacteriophage VLP platform displaying target epitopes from the macaque
CCR5 receptor. The immunogenicity of this vaccine will be assessed by determining
1) its ability to induce CCR5 peptide-specific systemic IgG antibodies upon
immunization of mice, 2) whether these antibodies are capable of recognizing and
binding the CCR5 receptor in its native conformation in vitro, and 3) whether serumderived antibodies are capable of inhibiting HIV-1 infection in vitro.
Aim 2. Induce mucosal immunity via pulmonary delivery of the vaccine. We will
nebulize the VLP-CCR5 vaccine developed in Aim 1 and deliver the aerosol to rats
via the pulmonary route. The ability of VLP-based vaccines to effectively translate to
aerosol and induce local and remote mucosal, as well as systemic, immunity will be
assessed.
Aim 3. Investigate alternate routes of mucosal immunization using, if necessary, a
variety of VLP conjugates. We will develop and investigate the effectiveness of
various immunization strategies using gel- and aerosol- based VLP vaccines applied
directly to the genital tract. Because primates are the only relevant animal model for
investigating protection from HIV infection, we will conduct preliminary
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investigations on the ability of genital vaccines targeting human papillomavirus 16
capsid proteins to elicit systemic and mucosal antibodies that are capable of providing
protection against infection in a mouse model.
Aim 4. Select optimal immunization strategy for viral challenge experiments in
macaques. Based on the results of the aforementioned aims, we will select an
appropriate mucosal VLP-based CCR5 vaccine and administer it to macaques.
Following immunization, macaques will be challenged with SIV via the genital tract
and the ability of the vaccine to prohibit or reduce infection will be determined. The
degree of protection conferred will be quantified by SIV viral loads in immunized
animals relative to control (unimmunized) animals.

2.6 Outline
The previous chapter provided extensive background on VLPs and their
employment in vaccine development. In Chapter 3, I describe the development of an
aerosolized, pulmonary VLP-based vaccine targeting one domain of CCR5 involved in
binding HIV, and analyze its efficacy in inducing a robust mucosal immune response.
Chapter 4 focuses on the development of a VLP-based vaccine for delivery to the genital
tract. In contrast to the pulmonary vaccine, which targeted a self-protein, the genital
vaccine targeted the human papillomavirus (HPV) type 16 capsid protein, L2.

In

targeting L2, we were able to study the ability of the vaccine to inhibit infection in a
mouse model. The success of the research described in Chapters 3 and 4 led to the
development of an aerosolized vaccine delivered directly to the genital tract of rhesus
macaques targeting two domains of CCR5.
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Whereas the pulmonary vaccine was

delivered in rats and therefore was not amenable to challenge in a relevant animal model,
we were able to conduct viral (SIV) challenges in the macaques and determine the
vaccine’s ability to 1) break B cell tolerance (evidenced by presence of anti-CCR5
antibodies) and 2) inhibit or prevent SIV infection. The progress of this ongoing work is
presented in Chapter 5. In Chapter 6, I expand upon the discussion of the previous
chapters, summarize the significance of my thesis research, address specific concerns and
limitations regarding my research, and propose additional experimental procedures that
may function to strengthen my previous findings. Finally, I discuss potential future
directions of this project based on my current findings.
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3.1. Abstract
Virus-like particles (VLPs) can be exploited as platforms to increase the
immunogenicity of poorly immunogenic antigens, including self-proteins.

We have

developed VLP-based vaccines that target two domains of the HIV coreceptor CCR5 that
are involved in HIV binding. These vaccines induce anti- CCR5 antibodies that bind to
native CCR5 and inhibit SIV infection in vitro. Given the role of mucosal surfaces in
HIV transmission and replication, we also asked whether an aerosolized, VLP-based
pulmonary vaccine targeting CCR5 could induce a robust mucosal response in addition to
a systemic response. In rats, both intramuscular and pulmonary immunization induced
high titer IgG and IgA against the vaccine in the serum, but only aerosol vaccination
induced IgA antibodies at local mucosal sites. An intramuscular prime followed by an
aerosol boost resulted in strong serum and mucosal antibody responses. These results
show that VLP-based vaccines targeting CCR5 induce high-titer systemic antibodies, and
can elicit both local and systemic mucosal response when administered via an aerosol.
Vaccination against a self-molecule that is critically involved during HIV transmission
and pathogenesis is an alternative to targeting the virus itself. More generally, our results
provide a general method for inducing broad systemic and mucosal antibody responses
using VLP-based immunogens.

3.2. Introduction
Many viral structural proteins can self-assemble into virus-like particles (VLPs)
that resemble infectious virus, but lack a viral genome and are therefore non-infectious.
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Because of their repetitive, multivalent structures, VLPs are highly immunogenic and
make excellent vaccines for the virus from which they were derived; the human
papillomavirus (HPV) and hepatitis B virus (HBV) vaccines are two examples of VLPbased vaccines. VLPs can also be adapted as platforms for display of antigens that are
either not normally or poorly immunogenic. Heterologous antigens displayed in a highly
dense, multivalent format on the surface of VLPs are extremely immunogenic; VLPdisplayed antigens can induce high titer antibody responses at low doses and in the
absence of exogenous adjuvants (Spohn and Bachmann 2008). VLP display can even be
used to induce antibody responses against self-antigens, essentially abrogating the
mechanisms of B cell tolerance (Chackerian, Lowy et al. 2001; Chackerian, Lenz et al.
2002; Chackerian, Durfee et al. 2008). This observation has led to the development of a
new class of vaccines that target self-molecules involved in a variety of chronic diseases,
including Alzheimer’s Disease (Chackerian, Rangel et al. 2006; Ambuhl, Tissot et al.
2007), hypertension (Li, Cao et al. 2004; Zamora, Handisurya et al. 2006) and
rheumatoid arthritis (Chackerian, Lowy et al. 2001; Spohn, Guler et al. 2007).
As an alternative strategy to conventional HIV vaccines, we have been interested
in using VLP display technology to target CCR5, a self-molecule that is critically
involved in HIV acquisition. During infection, HIV uses chemokine coreceptors in
addition to its primary receptor, CD4, to gain entry into cells (Alkhatib, Combadiere et al.
1996; Doranz, Rucker et al. 1996; Deng, Unutmaz et al. 1997). Although HIV can use
several coreceptors, CCR5 is the most physiologically important. In the early stages of
infection, the virus strains isolated are exclusively CCR5-tropic, suggesting a possible
selective advantage for these viruses during transmission or during the early stages of
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disease (Li, Juarez et al. 1999).

Furthermore, individuals harboring a homozygous

genetic mutation of the CCR5 allele (termed Delta-32) are resistant to HIV infection, and
infected heterozygous individuals (who express lower levels of CCR5) progress more
slowly to AIDS (Liu, Paxton et al. 1996; Samson, Libert et al. 1996; Winkler, Modi et al.
1998).

In 2008 the first small molecule CCR5 inhibitor, Maraviroc (Pfizer), was

clinically approved. Maraviroc binds to CCR5 and changes its conformation so that it is
not recognized by the coreceptor binding sites present on the HIV envelope glycoprotein,
gp120.

HIV infected patients receiving Maraviroc monotherapy have dramatically

decreased viral loads, often to undetectable levels (Fatkenheuer, Pozniak et al. 2005;
Hunt and Romanelli 2009; Yost, Pasquale et al. 2009). These data, in addition to the
effects of the Delta-32 mutation on HIV infection, indicate that a reduction in the
availability of functional CCR5 on target cells profoundly affects viral pathogenesis.
Unlike most viral vaccine targets, which mutate rapidly during the course of
infection, CCR5 is a cellular protein and therefore genetically stable. We hypothesized
that a vaccine that targeted CCR5 - either by limiting its expression on the cell surface or
by blocking virus-receptor interactions - could block viral replication and affect viral
pathogenesis.

A number of vaccine strategies targeting CCR5 have been tested,

including the use of a recombinant Flock House Virus that contains a CCR5 epitope
(Barassi, Soprana et al. 2005), a CCR5-HSP70 fusion protein immunogen (Bogers,
Bergmeier et al. 2004; Bogers, Bergmeier et al. 2004), a DNA vaccine consisting of
human CCR5 fused to tetanus toxoid (Zuber, Hinkula et al. 2000), and a CCR5 peptide
conjugate vaccine (Misumi, Nakayama et al. 2006), among others. Our laboratory has
developed several VLP-based vaccines to induce anti-CCR5 antibodies in which CCR5

30

epitopes are conjugated to the surface of pre-formed VLPs. We have previously shown
that a papillomavirus (PV) VLP-based vaccine targeting the N-terminal extracellular
domain of macaque CCR5 induced antibodies that bound to native CCR5 and blocked
HIV infection in vitro (Chackerian, Lowy et al. 1999). Although this initial study was
complicated somewhat by the low fitness of the challenge SHIV virus, prophylactic
vaccination of macaques with the VLP-CCR5 vaccine reduced viral loads and time to
clearance in pig-tailed macaques infected with a CCR5-tropic SHIV (Chackerian, Briglio
et al. 2004).

These data, and similar data from Misumi and colleagues (Misumi,

Nakayama et al. 2006), suggest that prophylactic vaccination against CCR5 may play a
role in controlling viral replication in a SHIV/macaque model. In this study, we have
developed second generation vaccines based on CCR5-derived peptides conjugated to
bacteriophage VLPs. These vaccines target multiple domains of CCR5.
Most current vaccines are administered by intramuscular (IM) or subcutaneous
injection. While these routes of immunization are extremely effective for the induction
of systemic immunity, they generally result in poor mucosal immune responses. Most
infectious pathogens, including HIV, enter the body and infect target cells at mucosal
surfaces, so an ideal vaccine against HIV would induce both systemic and mucosal
immune responses. Both the genital and gastrointestinal mucosa play crucial roles in the
establishment of HIV infection, either as a site of transmission (at the vaginal or rectal
mucosa) or as an important and critical site of viral replication and amplification seeding
the bloodstream (in the gastrointestinal mucosa) (Veazey and Lackner 2003).
We have been interested in examining the ability of VLP-based immunogens to
induce mucosal immune responses. In particular, we have investigated the effectiveness
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of pulmonary vaccination using aerosolized VLP-vaccines in inducing broad immune
responses. Aerosol delivery to the lung has a number of advantages. First, the lower
respiratory tract contains abundant antigen-presenting cells, predominantly pulmonary
macrophages and dendritic cells, which play important roles in priming adaptive immune
responses.

Second, although the mucosal immune system is, by and large,

compartmentalized, pulmonary vaccination results not only in local mucosal responses in
the lung, but also can give rise to strong mucosal responses in the genital/vaginal mucosa
(Holmgren and Czerkinsky 2005). Third, previous studies have shown that mucosal
immunization can in turn induce systemic immunity, which could eliminate the need for
an intramuscular immunization (Levine 2003).
In this study, we compared the immune responses induced by VLP-based
vaccines targeting macaque CCR5 upon intramuscular and pulmonary immunizations.
Both routes of immunization resulted in high-titer antibody responses against the vaccine
preparation, and anti-CCR5 antibodies were effective at blocking SIV infection.
However, only aerosol exposure led to the induction of local mucosal antibody responses.

3.3. Materials & Methods
3.3.1 CCR5-VLP preparation
A 21 amino acid peptide (designated EC1) representing the N-terminal 21 amino
acids (MDYQVSSPTYDIDYYTSEPC; sulfated at Y10 and Y14) of pig-tailed macaque
CCR5 (ptCCR5) was synthesized by American Peptide (Sunnyvale, CA), and then
directly linked to Qß bacteriophage using a bifunctional cross-linker (SMPH, Pierce
Endogen, IL), as described previously (Chackerian, Lenz et al. 2002). A second, smaller
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peptide representing the second extracellular loop (ECL2) of ptCCR5 was synthesized by
Celtek Peptides (Nashville, TN). The ECL2 peptide (DRSQREGLHYTG) is a cyclic
peptide spanning amino acids 168 - 177 of ptCCR5 in which the Arg and Thr residues are
linked through an Asp-Gly dipeptide spacer. As with the EC1 peptide, the ECL2 peptide
was linked to Qß bacteriophage via SMPH. Qß-EC1 VLP preparations, both prior to and
after nebulization, were visualized by electron microscopy. VLPs were adsorbed to
carbon-coated grids, stained with 1% uranyl acetate, and then were examined with a
Philips electron microscope model EM400RT at magnification x36,000.

3.3.2 Animal inoculations
Intramuscular
6-8 week-old female rats (Harlan Sprague Dawley, Indianapolis, IN) were
inoculated with 15 !g of Q!-EC1 VLPs in incomplete Freund’s adjuvant (IFA). 6-8
week-old female C57Bl/6 mice were inoculated with either 10 !g of Q!-EC1 or Q!ECL2 VLPs, or 5!g of each VLP preparation, in incomplete Freund’s adjuvant (IFA).
Inoculations were administered intramuscularly as shown in Table 1. Serum samples
(approximately 0.1-0.2 mL) were collected one week following the 1st and 2nd
immunization, and every week following the 3rd immunization (in rats) until sacrifice.
Aerosol
Groups of rats were each exposed to 0.1 mg of Q! or Q!-EC1 nebulized VLPs
(for a total of 0.3 mg in 5mL of phosphate-buffered saline (PBS) in a nose-only exposure
chamber (InTox, Albuquerque, NM). The chamber incorporated an aerosol pathway that
provides individual supply and exhaust routes in order to ensure uniform delivery of the
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test atmosphere. Compressed air was used for both nebulization air and dilution air to
ensure adequate air supply. The chamber pressure was maintained just below zero during
the dosing. Doses were determined by sampling the nose-only chamber and quantifying
the aerosol concentration and using the following equation: Dose = (Aerosol
concentration x Respiratory minute volume x Exposure time) / Body weight. Aerosol
particle size was determined using a laser diffraction particle size analyzer (Sympatec,
Germany). The median diameters of the aerosols were between 0.8 and 1.2 microns, thus
ensuring predominant respiratory deposition in rodents(Roy, Hale et al. 2003). Rats were
acclimated to aerosol exposure restraint tubes prior to the initial exposure. Shown in
Table 3.1, two groups (Qß-immunized rats and Qß-EC1 immunized rats) received an IM
prime as their first inoculation, with three subsequent aerosol boosts. Two additional
groups (Qß-EC1 immunized rats) received only aerosol inoculations, either with or
without Cholera Toxin B (CTB) adjuvant. Serum samples were collected as described
above unless otherwise indicated (IM prime groups). Animals were housed three per
cage in autoclaved, ventilated cages (Tecniplast, Phoenixville, PA) containing autoclaved
Tek-Fresh bedding (Harlan). The animals had ad libitum access to irradiated chow
(Harlan) and autoclaved water.

All animal care and experimental protocols were in

accordance with the National Institutes of Health and University of New Mexico School
of Medicine guidelines.

3.3.3 Quantifying antibody responses
Sera, feces, uterine washes and and bronchial-alveolar lavage fluid (BAL) were
tested for antibodies specific for the CCR5-EC1 peptide and Q! bacteriophage VLPs by
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ELISA. Briefly, Immulon II ELISA plates (Dynex Technologies, Chantilly, VA) were
coated overnight at 4°C with either 0.5 !g of bovine serum albumin (BSA)-conjugated
EC1 peptide or 0.5 !g Q! VLPs per well. Wells were then blocked with 50 !L of PBS
with 0.5% milk (w/v) per well for 2 h at room temperature. An initial 1:40 dilution of
serum was serially diluted 4-fold and applied to wells for 2.5 h at room temperature. (All
dilutions were done in 0.5% milk (w/v) in PBS unless otherwise noted.) Reactivity to
target peptides was determined by using horseradish peroxidase (HRP)-labeled goat antirat IgG (Jackson Immunoresearch, Bar Harbor, ME) at a dilution of 1:2000 and incubated
for 1 h at room temperature. Upon development, the optical density at 405nm (OD405)
was determined using a Thermo Max microplate reader (ThermoLab Systems, Fisher
Scientific, Pittsburgh, PA).

Absorbancies greater than twice the background were

considered positive. ELISAs for IgA in sera were conducted as above, incorporating the
following changes: sera was diluted 1:10 in PBS with 0.5% BSA, and presence of
antibodies was detected using HRP-labeled goat anti-rat IgA (Open Biosystems,
Huntsville, AL). For ELISA analysis of BAL fluids, feces and uterine washes, samples
were diluted 1:1 in PBS and the OD405 determined.

3.3.4 ELISPOT
96-well ELISpot plates were activated with 70% ethanol according to
manufacturer’s instructions (Millipore, Billerica, MA) and coated overnight at 4°C with
0.5 !g Q! VLPs or BSA-EC1 peptide. Lungs were harvested, perfused and processed for
lymphocyte isolation as previously described (Swanson, Zheng et al. 2004). 4x105 cells
per well were plated in complete RPMI and incubated overnight at 37°C. Wells were
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washed three times with 0.5% fetal calf serum (FCS) in PBS and the appropriate HRPlabeled goat anti-rat secondary (IgG or IgA) antibody was added at a 1:1000 dilution.
Following a 2 h incubation at room temperature, wells were washed as described above
and developed with TMB substrate (MABtech, Mariemont, OH) until spots appeared.
Spots were quantitated using an AID ViruSpot/EliSpot Reader (Cell Technology, Inc.,
Columbia, MD).

3.3.5 Flow cytometry
Binding to CCR5 was tested by incubating pooled sera from immunized mice
with 293T cells that were transiently transfected (or mock-transfected) with a pig-tailed
macaque CCR5 expression vector (obtained from the NIH AIDS reference and reagent
program). Two days after transfection, CCR5-expressing 293T cells were detached from
the plate using 0.5mM EDTA and then washed three times in FACS buffer (0.5% BSA in
PBS). Cells were incubated with Protein G-purified IgG isolated from the pooled sera of
mice immunized with Qß VLPs, Qß-EC1, or Qß-ECL2. Approximately 105 cells were
resuspended in 100 µL of staining buffer and then incubated with 10-20 µL of purified
mouse IgG followed by a fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG
(Jackson Immunoresearch, West Grove, PA). As a positive control, cells were incubated
with a phycoerythrin (PE)–labeled anti-human CCR5 monoclonal antibody (3A9; BD
Biosciences, San Jose, CA). Flow cytometric analysis was performed on a FACS Calibur
by using the Cell Quest software package (BD Biosciences, San Jose, CA). Specific IgG
binding was measured relative to mock-transfected cells.
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3.3.6 SIV inhibition assay
SIVmac251 inhibition was measured using MAGI-ptCCR5 indicator cells
(Kimata, Gosink et al. 1999) pretreated with heat-inactivated sera from immunized mice
for 30 minutes at 37 degrees and then infected with approximately 100 infectious
SIVmac251 particles (obtained from the NIH AIDS Research and Reference Reagent
Program). Two days after infection, infected cells were scored by counting the number of
blue cells in each well. Inhibition of SIV infection was determined by comparing the
number of blue (infected) nuclei in the presence of antibody versus the number of blue
nuclei in the absence of sera.

3.4 Results
3.4.1 Vaccine Preparation
Antigens displayed at high density on the surface of VLPs are highly
immunogenic. We have used the VLP-display approach to develop vaccines targeting
the HIV/SIV coreceptor CCR5. Because of their role in HIV binding to CCR5 (Edinger,
Amedee et al. 1997; Wu, LaRosa et al. 1997), we targeted the N-terminal extracellular
domain of CCR5, also referred to as extracellular domain 1 (EC1), and a domain from
extracellular loop 2 (ECL2).

For the EC1 vaccine, a 21 amino acid peptide

corresponding to the amino region of EC1 of pig-tailed macaque (pt) CCR5 was
synthesized. The tyrosines at positions 10 and 14 of the peptide were sulfated to reflect
the fact that sulfation of these residues in native CCR5 is thought to be important in HIV
binding (Farzan, Mirzabekov et al. 1999). The ECL2 peptide is a cyclic peptide spanning
amino acids 168 - 177 of ptCCR5 in which the Arg and Thr residues are linked through
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an Asp-Gly dipeptide spacer. This peptide was originally identified as an immunogen
capable of inducing anti-CCR5 antibodies by Misumi and colleagues (Misumi, Nakajima
et al. 2001). The EC1 and ECL2 peptides were chemically conjugated to VLPs derived
from an RNA bacteriophage, Qß, using a bifunctional crosslinker, SMPH, that allowed us
to link the C-terminal cysteine on the peptides to exposed surface lysine residues on the
coat protein of Qß (Figure 3.1 A). The extent of conjugation was determined by analysis
of denatured particles by gel electrophoresis (Figure 3.1 B).

Figure 3.1: Generating the Qß-EC1 vaccine

Figure 3.1. Generating the CCR5 vaccines. A) EC1 and ECL2 peptides were linked to Qß
VLPs through the use of a bifunctional crosslinker (SMPH). SMPH crosslinks surface
lysines on Qß VLPs to a cysteine located at the C-terminus of the EC1 peptide or the base of
the cyclized ECL2 peptide. Non-CCR5 derived amino acids are highlighted in grey.
Numerous copies of peptide can be attached per coat protein, resulting in peptide
presentation in a dense and repetitive array on the VLP surface. B) Polyacrylamide gel
analysis of denatured Qß VLPs (lane 1), EC1-conjugated Qß VLPs (lane 2), and ECL2conjugated Qß VLPs (lane 3). Qß VLPs are comprised of a single protein subunit, coat
protein, which migrates with a mobility corresponding to its molecular weight, ~14000
Daltons. Conjugation of the EC1 peptide results in higher molecular weight species,
representing individual coat protein subunits modified with 1 (+1), 2 (+2), or 3 (+3) copies
of the peptide.
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Peptide-modified Qß coat protein displays a mobility shift relative to unmodified
Qß coat protein. The degree of the mobility shift reflects the addition of one, two, or
three peptides per coat protein molecule. As is shown in Figure 3.1 B, the majority of
coat protein has been modified with peptide. We estimate that the average Qß-ECL2
vaccine preparation contains 1.5 copies of peptide per coat protein and the Qß-EC1
preparation contains greater than 0.5 copies of peptide per coat protein, resulting in a total
of ~270 (ECL2) or >90 (EC1) peptides being presented on the VLP surface. In either
case, our earlier studies have indicated that these densities of peptide on the surface of the
VLPs should be sufficient to induce a strong antibody response (Chackerian, Lenz et al.
2002; Peabody, Manifold-Wheeler et al. 2008).

Table 3.1: Experimental design for pulmonary immunizations
Species

Inoculum

Delivery & Dose

Vaccination Schedule

Sacrificed
@

Mice

Q!-EC1

IM + IFA (10 µg)

Weeks 0, 2

6 Weeks

Mice

Q!-ECL2

IM + IFA (10 µg)

Weeks 0, 2

6 Weeks

Rats

Q!

Rats

Q!-EC1

IM prime (15µg) +
Weeks 0 (IM), 2, 6,15 (A)
aerosol boost (100µg)
IM prime (15µg) +
Weeks 0 (IM), 2, 6,15 (A)
aerosol boost (100µg)

Rats

Q!-EC1

IM only (15µg)

Weeks 0, 2

6 Weeks

Rats

Q!-EC1

Aerosol only (100µg)

Weeks 0, 2

6 Weeks

Rats

Q!-EC1

Aerosol + CTB
adjuvant (100µg)

Weeks 0, 2

6 Weeks

39

27 Weeks
27 Weeks

3.4.2 VLP-based CCR5 vaccines are immunogenic
We determined whether Qß-EC1 and Qß–ECL2 could elicit anti-CCR5 antibody
responses upon intramuscular (IM) immunization. Groups of three to seven mice were
immunized with Q!-EC1 and/or Qß–ECL2 as shown in Table 3.1.
Briefly, animals were given two doses of 10 !g total inoculum (mice immunized
concurrently with Qß-EC1 and Qß –ECL2 received 5 !g of each), at a two-week interval
and then sera were collected weekly and analyzed for antibodies specific to the EC1 and
ECL2 peptides by end-point dilution ELISA (Figure 3.2). Immunization with either QßEC1 or Qß –ECL2 elicited high-titer (geometric mean titer = ~104) IgG antibodies
specific to the peptide of interest, but not against the other peptide. Animals immunized
with Qß VLPs alone did not produce antibodies that recognized either of the CCR5
peptides. Simultaneous immunization with Qß-EC1 and Qß–ECL2 elicited high-titer IgG
antibodies against both CCR5 peptides.

Figure 3.2: Serum antibody responses to intramuscular immunization of rats with
Qß-EC1 particles

Figure 3.2. IgG antibody responses in C57Bl/6 mice immunized three times at 2 week
intervals with 5 !g wild-type Qß VLPs, Qß conjugated to the CCR5 N-term peptide
(Qß-EC1), Qß conjugated to the cyclic ECL2 peptide (Qß-ECL2), or a mixture of QßEC1
3.4 plus Qß-ECL2. This figure shows end-point dilution IgG ELISA titers for sera
taken two weeks after the final immunization against peptides representing the CCR5
EC1 (right panel) or ECL2 (left panel). Each data point represents the antibody titer
from an individual mouse. Lines represent the geometric mean titer for each group.
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3.4.3 Anti-CCR5 antibodies bind native CCR5 in vitro and inhibit SIV infection
Although these data indicated that the two CCR5 peptide-conjugated VLP
vaccines elicited antibodies that recognized ptCCR5 peptides, it was possible that these
antibodies might not recognize the EC domains in their native conformation on
membrane-associated ptCCR5. To examine this question, the ability of anti-EC region
antibodies to bind to membrane-associated ptCCR5 was assessed by flow cytometry.
IgG was purified from the pooled sera of Qß-EC1 or Qß-ECL2 intramuscularly
immunized mice and incubated with ptCCR5- or mock-transfected 293T cells.

Figure 3.3: Q!-EC1 antibodies bind to native CCR5 receptor in vitro

Figure
3.3.
Q!-EC1
antibodies bind to native
CCR5 in vitro. 293T cells
were mock-transfected (solid
line) or transfected with pigtailed macaque CCR5 (dashed
line).
Two days after
transfection,
cells
were
incubated with (A) a PElabeled monoclonal antibody
(3A9) that binds to the EC1
domain of CCR5, (B)
secondary antibody alone, (C)
pooled protein G-purified IgG
from Q!-immunized mice,
(D) protein G-purified IgG
from Q!-EC1 immunized
mice, and (E) protein Gpurified IgG from Q!-ECL2
immunized mice, and then
antibody binding was assessed
by
flow
cytometry.
Geometric mean fluorescence
values are shown below each
panel.
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As a positive control, some cells were incubated with 3A9, a monoclonal antibody that
binds to the EC1 domain of CCR5.

As a negative control, transfected cells were

incubated with purified IgG from the sera of mice immunized with Qß VLPs alone. As
shown in Figures 3.3 D and 3.3 E, IgG from the sera of Qß-EC1 and Qß-ECL2
immunized mice specifically bound to CCR5-expressing cells relative to mocktransfected cells, indicating binding of IgG to CCR5. There was no binding detected in
IgG purified from the sera isolated from Qß-immunized mice (Figure 3.3 C). Thus, both
Qß-EC1 and Qß-ECL2 vaccines elicited antibodies that recognize the conformation of
native CCR5 expressed on 293T cells.
To assess the ability of induced sera to inhibit SIV infection, we used a single
cycle infectivity assay utilizing the MAGI-ptCCR5 indicator cell line (previously
described) to determine whether antibodies elicited from our CCR5 vaccines could
inhibit SIV infection in vitro. Cells were incubated with increasing dilutions of heatinactivated sera from mice immunized intramuscularly with Qß-EC1, Qß-ECL2, both
Qß-EC1 and Qß-ECL2, or Qß VLPs alone and then infected with the CCR5-tropic strain
SIVmac251.
As shown in Figure 3.4, sera from animals immunized with either Qß-EC1 or
Qß-ECL2 inhibited SIVmac251 infection. Although anti-ECL2 and anti-EC1 antibodies
were somewhat weakly inhibitory individually, in combination they displayed 50%
inhibition at a 1:40 serum dilution. Although this inhibition titer is not particularly high,
it is important to recognize that inhibition of virus infection by blocking the receptor is a
much more stringent task than blocking the virus. Every potential target cell expresses
multiple copies of CCR5.
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Figure 3.4: VLP-CCR5 IgG blocks SIV infectivity in vitro
Figure 3.4.
Inhibition of
SIVmac251
infection.
SIVmac251
inhibition was
measured using
MAGI-ptCCR5
indicator cells
pretreated with sera
from immunized
mice for 30
minutes at 37
degrees and then
infected with
approximately 100 infectious SIVmac251 particles. Two days after infection, infected
cells were scored by counting the number of blue cells in each well. Inhibition of SIV
infection was determined by comparing the number of blue (infected) nuclei in the
presence of purified IgG versus the number of blue nuclei in the absence of IgG. Data
represents the average of two different experiments; error bars show standard error of the
mean.

3.4.4 Pulmonary immunization induces systemic antibodies against CCR5
To see whether our VLP-based vaccine could also induce antibody responses
upon mucosal immunization, we translated our intramuscular Qß-EC1 vaccine into an
aerosolized vaccine for pulmonary administration. We first wanted to determine whether
Qß-EC1 VLPs remained intact following the aerosolization process.

VLPs were

nebulized, recovered, and concentrated, and then visualized by electron microscopy. The
nebulized and recovered VLPs had similar morphology to un-nebulized VLPs (Figure
3.5).
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Pulmonary immunizations were carried out in to 6-8 week-old female rats. We
used rats because they have larger tidal volumes than mice, thereby inspired particles are
better able to reach the lower respiratory tracts in this species (Parent 1992). Particles
that reach the lower respiratory tracts are more difficult to expel, and are in a milieu rich
in antigen-presenting cells ideal for initiating an immune response throughout mucosal
tissues. Since the induction of anti-CCR5 antibodies in the genital tract was also a
primary aim, female rats were chosen so that uterine washes could be collected (along
with sera) throughout the study, and the uterus later recovered and analyzed.

Figure 3.5: Q!-EC1 virus-like particles survive nebulization

Figure 3.5. Q!-EC1 virus-like particles survive nebulization. Qß-EC1 was nebulized
and then captured and reconcentrated by filter centrifugation. Particles were then
adsorbed to carbon-coated grids, were stained with 1% uranyl acetate, and were
examined with a Philips electron microscope model EM 400RT at magnification
x36,000. Shown is Qß-EC1 prior to (A) or post-nebulization (B).
First, we assessed the antibody responses in rats immunized via the pulmonary
route. Rats received aerosol immunizations of 100 !g Qß-EC1 twice at a two-week
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interval. One group of rats was immunized with Qß-EC1 formulated with 25 µg of
cholera toxin B (CTB). CTB is a non-toxic and recombinantly produced cholera toxin Bsubunit that has been reported to have mucosal adjuvant properties. Sera was collected
every week until necropsy and IgG and IgA antibodies against Q! and EC1 were
quantitated by end-point dilution ELISA and compared to the antibody responses elicited
by intramuscular (IM) immunization. As shown in Figure 3.6, aerosol administration of
Qß-EC1 elicited anti-EC1 and anti-Qß IgG and IgA antibodies that were comparable to
those elicited when the vaccine was delivered intramuscularly. Coadministration of CTB
adjuvant had slightly enhanced IgG titers, but elicited no appreciable difference in IgA
titers. Rats given IM immunizations had the highest titers against the VLP platform, but
had similar anti-EC1 antibody levels as those measured in rats receiving the aerosolized
vaccine.
We also wanted to determine whether systemic antibody responses could be
increased by “priming” rats with an initial IM immunization followed by an aerosol
boost. Groups of rats were immunized with two IM injections, two aerosol exposures, or
an IM prime followed by an aerosol boost.

One week following the second

immunization, sera was collected and IgG and IgA titers against the EC1 peptide were
measured (Figure 3.7 A). Rats receiving two IM immunizations had the highest serumassociated IgG levels against EC1, but had lower IgA levels. In contrast, rats receiving
two aerosol immunizations had lower IgG levels, but higher IgA antibodies.

Rats

receiving the prime/boost regimen had an intermediate response that achieved a balance
between the two other immunization strategies. The IM prime group displayed a 10-fold
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increase in IgA titers as compared to rats given only IM immunizations; there was also a
moderate increase in IgA titer compared to the group receiving the aerosolized vaccine.

Figure 3.6: Systemic IgG and IgA responses in rats immunized with Q!-EC1 VLPs

Figure 3.6. Systemic IgG and IgA responses in rats immunized with Q!-EC1 VLPs.
Groups of three rats were immunized intramuscularly (squares) or via the pulmonary
route with (triangles) or without (circles) CTB adjuvant. Immunizations were carried out
on days 0 and 14, sera were collected at the time points indicated, and antibody levels
were determined by end-point dilution ELISA. Shown are (A) anti-Q! IgG, (B) anti-Q!
IgA, (C) anti-EC1 IgG, and (D) Anti-EC1 IgA antibody titers. The data shows the
geometric mean titer of three immunized rats and error bars represent SEM.
Moreover, the level of IgG elicited by the IM group was not lower in the IM
prime group, and was slightly higher than that seen in animals receiving only pulmonary
immunizations. To investigate the longevity of the immune response and the efficacy of
a boost in evoking memory, we continued collecting sera from the prime/boost group
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over 27 weeks. Animals in this group were given additional aerosol boosts at weeks 6
and 15, and then sacrificed 27 weeks after the initial immunization. IgG titers against
EC1 were sustained, and remained above 103 for 12 weeks following the final boost in all
three animals (Figure 3.7 B). Serum anti-EC1 IgA antibodies diminished more rapidly,
perhaps reflecting the shorter half-life of this molecule.

However, aerosol boosts

increased IgA antibody levels to peak titers (104) in 2 out of 3 animals.
Figure 3.7: Antibody titers in rats receiving an IM prime followed by aerosol boosts
of Q!-EC1 VLPs

Figure 3.7. Antibody titers in rats receiving an IM prime followed by aerosol boosts of
Q!-EC1 VLPs. (A) Comparison of IgG and IgA serum anti-EC1 titers in rats one week
following a 2nd inoculation with Q!-EC1. Rats received 2 intramuscular inoculations, 2
inoculations via aerosol, or an intramuscular prime followed by an aerosol boost. Bars
represent the geometric mean titer of the group. (B) Kinetics of serum anti-EC1
responses in individual rats receiving an IM prime followed by aerosol boosts of Q!EC1. Rats were immunized on weeks 0, 2, 6, and 15 (arrows), sera collected at the time
points indicated and IgG (closed circles) and IgA (open circles) titers were determined by
ELISA.
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3.4.5

Pulmonary immunization enhances local antibody secretion in mucosal

tissues
Pulmonary administration of our Q!-EC1 vaccine was successful in inducing both
IgG and IgA antibodies in the blood, so we next asked whether antibodies specific to Q!
and EC1 were also present in mucosal secretions of animals immunized by the various
strategies described previously.

As an additional control, one group of rats was

immunized with Qß VLPs alone, via the IM prime/aerosol boosts regimen.

Figure 3.7: Anti-Q! and -EC1 titers in mucosal washes of immunized rats

Figure 3.8. Anti-Q! and -EC1 titers in mucosal washes of immunized rats. Bronchialveolar lavage fluid, feces, and uterine lavage samples were collected at necropsy,
diluted 1:1 in PBS, and anti -Q! and -EC1 IgG and IgA antibodies levels were measured
by ELISA. Rats were immunized with Q!-EC1 via the intramuscular route (black), the
pulmonary route with or without CTB adjuvant (dotted or lined fill, respectively), or
given an IM-prime followed by aerosol boosts (no fill). As a negative control, a fifth
group was given an IM prime followed by aerosol boosts of QB VLPs alone (grey).
Shown are (A) anti-Q! IgG, (B) Anti-Q! IgA, (C) anti-EC1 IgG, and (D) anti-EC1 IgA.
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At necropsy, we collected bronchi-alveolar lavage fluid (BAL), and we also collected
washes from the uterus and feces of the immunized rats. These samples were diluted 1:1
in PBS with 0.5% BSA, and then anti–Q! and –EC1 IgG and IgA antibodies were
measured by ELISA (note: we did not test the anti-Qß antibody responses of the
prime/boost group because of a limited amount of material). As was observed in the sera,
rats given the IM vaccine alone and the IM prime/aerosol boost regimen had the highest
IgG levels in all three mucosal sites tested (Figures 3.8 A, C). Rats immunized via the
aerosol route alone had relatively high IgG titers in uterine washes, but surprisingly low
IgG levels in BAL fluid. However, only those animals immunized with the aerosolized
vaccine secreted IgA at the mucosal sites tested (Figures 3.8 B, D)--essentially no IgA
response was induced by IM immunization. Co-administration of CTB adjuvant with the
aerosolized vaccine somewhat boosted secreted IgG levels relative to aerosol alone, but
did not have a pronounced impact on IgA levels in secretions. In general, the IM
prime/aerosol boost regimen induced the strongest anti-EC1 antibody response,
particularly in the lung.

3.4.6 CCR5-specific B cells in the lung following pulmonary immunization
After determining that pulmonary immunization could confer systemic immunity
as well as mucosal immunity in remote tissues, we assessed the local immune response
more quantitatively by determining the number of antibody-specific B cells in the lung by
ELISPOT. Lungs were collected from animals receiving only aerosol immunizations or
only IM immunizations of Q!-EC1, and processed as previously described for
lymphocyte collection (Swanson, Zheng et al. 2004). ELISPOT analysis was performed
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on plated B cells and the number of IgG- and IgA- secreting B cells specific for either Q!
or EC1 quantified. As a control, some animals were immunized with Q! VLPs alone.
Consistent with what was observed in mucosal washes, only animals receiving the
aerosolized vaccine had detectable Q!- and EC1-specific B cells. Animals receiving an
IM administration of the vaccine had few Q!-specific IgG secreting B cells in the lung,
and no EC1-specific B cells. Coadministration of CTB did not enhance the frequency of
EC1-specific B cells, and, if anything, seemed to a have a negative effect (Figure 3.9), in
contrast to the neutral and/or positive effects observed in the sera and mucosal washes.
Rats given the inhaled Q!-EC1 vaccine without adjuvant had nearly equal amounts of
IgA secreting B cells against both Q! and EC1, and comparable numbers of IgGsecreting B cells as well, indicating an immune response against both platform and target.

3.5 Discussion
Development of a prophylactic HIV vaccine is an important component in
battling the worldwide HIV epidemic, but the path towards this goal has been fraught
with difficulties. Viral sequence diversity and antigenic variation are major and perhaps
insurmountable barriers in the development of vaccines based on the induction of
humoral and/or cellular immunity against the virus.

As an alternative strategy to

conventional HIV vaccines, we have been interested developing a vaccine that targets
CCR5, a self-molecule that is critically involved in HIV acquisition, and which is not
subject to antigenic variation. However, because CCR5 is a self-protein, the ability to
initiate an antibody response against the molecule is seemingly limited by the
mechanisms of B cell tolerance, which normally prevent the induction of antibody
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responses against self-molecules. In spite of this, we and others have shown that by
arraying self-molecules at high density on the surface of virus-like particles (VLPs) we
can completely abrogate these tolerance mechanisms and induce high titer IgG antibodies
against diverse self-antigens (Chackerian 2007; Jennings and Bachmann 2009).

Figure 3.9: Aerosol exposure, but not intramuscular immunization, results in
vaccine specific B cells in the lung

Figure 3.9. Aerosol exposure, but not intramuscular immunization, results in vaccine
specific B cells in the lung. Lymphocytes were isolated from lungs of rats receiving
intramuscular or pulmonary deliveries of Q!-EC1 either with or without CTB adjuvant.
Cells were analyzed by ELISPOT for IgG (A) and IgA (B) secreting Q!-specific and
EC1-specific B-cells. As a positive control, one group received an IM prime followed by
aerosol boosts of Q! VLPs alone (Far right sample, Q! only).
Our laboratory has taken advantage of these findings to develop several VLPbased vaccines that elicit anti-CCR5 antibodies.
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Previously, we developed a

papillomavirus (PV) VLP-based vaccine targeting the N-terminal extracellular domain of
macaque CCR5 that induced anti-CCR5 antibodies in macaques that bind to native CCR5
and blocked HIV infection in vitro. Moreover, prophylactic vaccination of macaques
with this vaccine reduced viral loads and time to clearance in pig-tailed macaques
infected intravenously with a CCR5-tropic SHIV (Chackerian, Briglio et al. 2004).
Here, we show that bacteriophage VLP-based vaccines that target two
extracellular domains of macaque CCR5 that are involved in SIV/HIV binding induce
similarly high titer anti-CCR5 antibodies in rodents.

In this study, the question of

immune tolerance was not addressed, as we targeted macaque CCR5 in rodent models.
However we, and others, have shown that the ability to induce antibody responses in the
face of immune tolerance mechanisms is a general characteristic of VLP display
(Chackerian 2007; Jennings and Bachmann 2009). Moreover, several laboratories have
previously or are currently working on approaches to induce anti-CCR5 antibodies.
These include Lucia Lopalco’s laboratory, which has developed a recombinant Flock
House virus that presents a peptide derived from CCR5 ECL1 (Barassi, Soprana et al.
2005) and Tom Lehner’s laboratory, which has developed a CCR5-HSP70 fusion protein
immunogen (Bogers, Bergmeier et al. 2004; Bogers, Bergmeier et al. 2004), among
others. Three macaque challenge experiments have been reported; our own and the
previously mentioned Misumi study (Misumi, Nakayama et al. 2006), in which
vaccinated macaques were challenged with a SHIV isolate and which some degree of
viral inhibition was reported, and studies by Wahren and colleagues, in which DNA
vaccination with a construct containing human CCR5 fused to tetanus toxoid failed to
protect macaques from SIVsm challenge (Zuber, Hinkula et al. 2000).
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HIV, like many pathogens, most frequently establishes infection at mucosal
surfaces. As such, the efficient induction of mucosal immunity by vaccination, and
particularly the induction of local immunoglobulin production, including secretory IgA
(SIgA), will likely play an important role in future HIV-1 vaccine approaches (Mazzoli,
Trabattoni et al. 1997; Devito, Broliden et al. 2000). The genital and gastrointestinal
mucosa play crucial roles in the establishment of HIV infection, either as a site of
transmission or as an important site of early viral replication and amplification. Although
antibodies against CCR5 would presumably not act as classical neutralizing antibodies, it
is possible that they could block interactions between virus and the cells that are targeted
early in infection, specifically resident activated memory T cells or Langerhans cells
(LCs). LCs have been proposed to facilitate HIV infection by capturing virus, migrating
to regional lymph nodes, and then transferring virions to susceptible T cells. Although
LCs can interact with HIV via a variety of different surface receptors, it has been shown
that antibodies that bind CCR5 can partially block the uptake of HIV by LCs (Hladik,
Sakchalathorn et al. 2007). Low level CCR5-reactive antibodies (with virus inhibitory
activity in vitro) have been detected in the seronegative partners of HIV-infected
individuals, suggesting that anti-CCR5 antibodies may play a role in protection from
natural HIV infection (Lopalco, Barassi et al. 2000).
Numerous mucosal vaccination strategies have been investigated, including
administration of vaccines to oral, genital, rectal, and respiratory mucosal surfaces. The
mucosal immune system is largely compartmentalized, and the expression of mucosal
IgA typically occurs primarily at the site of vaccination (Holmgren and Czerkinsky
2005). Thus, the choice of a mucosal vaccination route needs to be tailored to the
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specific target. The respiratory tract is a particularly attractive site for immunization.
Not only does immunization of the respiratory tract stimulate a local mucosal antibody
response, but it can also elicit a strong genital mucosal immune response 23. Moreover,
administration of vaccines via aerosol to the nasal and bronchial lymphoid tissues is less
invasive than other approaches and may facilitate vaccine implementation.
A number of different studies in mice have shown that intranasal vaccination with
VLPs or VLP-based immunogens successfully results in local (in the lung) mucosal and
systemic antibody responses (Balmelli, Demotz et al. 2002; Barassi, Soprana et al. 2005;
Bessa, Schmitz et al. 2008). One advantage of aerosol over intranasal immunization is
that aerosol delivery allows for VLP deposition in the lower respiratory tract. The
trachea, lungs, and mediastinal lymph nodes act as the major immune inductive sites,
allowing for a robust systemic humoral response. The upper respiratory tract, represented
by the nasal-associated lymphoid tissue (NALT), although directly stimulated upon
intranasal immunization, in some cases appears to play a negligible role in the induction
of a mucosal immune response at distal sites (Balmelli, Roden et al. 1998; Balmelli,
Demotz et al. 2002; Revaz, Zurbriggen et al. 2007), although at least one report has
shown that nasal immunization can result in induction of IgA in the genital tract
(Johansson, Wassen et al. 2001). Immunization of the lower respiratory tract is more
effective at inducing genital antibody responses in mice (Balmelli, Roden et al. 1998).
Moreover, immunization of the lower respiratory tract may be particularly important in
inducing mucosal immunity in humans. For example, a comparative study of intranasal
versus aerosol immunization of humans with HPV16 VLPs demonstrated that nasal
immunization resulted in weak systemic and mucosal anti-VLP antibody responses. In
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contrast, bronchial aerosolization of HPV16 VLPs resulted in significantly higher
antibody levels and rates of seroconversion (Nardelli-Haefliger, Lurati et al. 2005).
Consequently, if the lower respiratory tract is not reached for antigen presentation during
intranasal immunization, it could account for reduced levels of mucosal, but not systemic,
VLP-specific humoral responses. In this study, we provide the first indication that a
VLP-based vaccine targeting a heterologous antigen can be aerosolized to effectively
induce IgG and IgA antibodies in both local and distal mucosal tissues. The presence of
Q!%specific IgG antibody in distant mucosal tissues following aerosol immunization
suggests that our vaccine was likely able to reach the lower respiratory tract.
We found that Q!-EC1 VLPs were able to survive nebulization and delivery in a
rat model, and that immunization via a pulmonary route was effective at generating both
anti-EC1 IgG and IgA antibodies in the sera, the lung, the genital tract, and, to a lesser
extent, the gastrointestinal (GI) tract.

Presence of IgA in the uterine washes is most

likely due to the upregulation of CCR10 on antibody producing cells, which allows for
migration from the respiratory tract-draining lymph node to the genital tract (Brandtzaeg
and Johansen 2005). Pulmonary immunization does not however typically result in
upregulation of CCR9, which directs homing to the intestine (Butcher, Williams et al.
1999; Bowman, Kuklin et al. 2002). While this could explain the decreased amounts of
IgG antibody found in the feces, the levels of IgA seen in both the uterine wash and the
feces is somewhat surprising. It is possible that some of the inoculum reached the GI
tract through animal inspiration during the aerosol exposure.
In accordance with the secreted antibody levels observed in the sera and mucosal
tissues following pulmonary immunization, rats receiving the aerosolized vaccine were
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also able to maintain high levels of Q!-EC1 specific B cells in the lung, as well as
detectable levels in the spleen and uterus 55 days following final exposure (data not
shown). Similar to our study, Bessa et al. recently compared subcutaneous and intranasal
deliveries of Q! VLPs in mice and found that while both routes were effective at
generating specific IgG in the serum, only the intranasal route of vaccination yielded Q!specific IgA in BAL; levels of mucosal IgG were also generally higher in these mice as
compared to the s.c. group (Bessa, Schmitz et al. 2008). Bessa also showed that the
numbers of IgG antibody-forming cells in the mesenteric lymph node were higher in
mice receiving i.n. immunization of Q! VLPs, which parallels our finding that aerosol
immunization yields higher numbers of Q! VLP- and EC1-specific B cells in the lung
itself.
Unexpectedly, use of the mucosal adjuvant CTB did not appear to enhance
immune responses at mucosal sites. Indeed, in some cases, CTB actually dampened
antibody levels when compared to the group receiving the aerosolized vaccine without
adjuvant. It is possible that the CTB was delivered to different mucosal compartments
than the VLPs, or simply that CTB is not compatible with the nebulization process and
thus not an appropriate adjuvant for aerosol delivery. Previously, Nardelli et al looked at
the ability of mucosal adjuvants to increase both serum-specific IgG and mucosal IgA
titers following “aerosol-like” vaccination. In this protocol, mice were anesthetized and
immunized with HPV VLPs and either heat labile enterotoxin (HLT) or CpG
oligodeoxynucleotides, following priming with influenza peptides. HLT proved a potent
adjuvant and was able to increase VLP-specific IgG in the serum by more than 10-fold
(Revaz, Zurbriggen et al. 2007). Furthermore, use of HLT was able to restore IgG and
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IgA titers in both sera and mucosa that were previously obtained following vaccination
with HPV VLPs and CTB adjuvant (without influenza priming). In contrast to our
results, these prior experiments with CTB were successful, however titers were higher
when HLT was used. The success of this adjuvant could be due to its ability to induce
both Th1 and Th2 responses, as well as SIgA and serum IgG and IgA responses (Freytag
and Clements 2005). Recent studies have shown that when CTB is used (along with
whole cholera toxin [CT]) as a vector, it can give rise to either mucosal immunity or
induce peripheral anti-inflammatory tolerance to chemically or genetically linked foreign
antigens administered mucosally. More specifically, CTB seems to steer the immune
response towards Th2-only immunity or tolerance, while CT favored a broad Th1 + Th2
+ CTL immunity (Sanchez and Holmgren 2008). The use of HLT instead of CTB may
enhance the IgA titers induced by VLP-based immunogens.
Use of the VLP-based approach for vaccine delivery to the mucosa-associated
lymphoid tissue (MALT) has widespread applicability, with relevance to virtually any
pathogen infecting at a mucosal surface.

A vaccine that elicits both IgA and IgG

antibodies at the site of infection prior to exposure could be a powerful deterrent to viral
entry and subsequent infection. The innate immunogenic properties of VLPs provide a
useful mechanism to generate antibody responses against poorly antigenic molecules both
systemically and in the respiratory tract. The simultaneous flexibility and stability of
VLPs offer further advantages with regard to mucosal vaccine design. The very type of
VLP used for a particular vaccine can be catered to both its destination within the
mucosa/environment and to the conjugate antigen, if applicable. For example, VLP size,
surface chemistry, and tolerance for antigen insertion or conjugation are all factors in
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vaccine design that can be readily manipulated for optimal efficacy. Translating this
technology for non-invasive aerosolized delivery, with the result of an enhanced mucosal
immune response, significantly broadens its applicability.
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4.1 Abstract
A strong mucosal immune response is desirable for combating pathogens which
infect at mucosal surfaces. We had previously shown in rats that immunization via a
pulmonary route with an aerosolized VLP-based vaccine elicited a local mucosal
antibody response in the lung, as well as a weaker, but measurable, response in the
genital tract. In this study, we examined whether direct immunization of the mouse
genital tract with a VLP vaccine could induce robust mucosal and systemic antibody
responses. We also investigated the importance of the type of VLP platform in inducing
an immune response. Specifically, we asked whether the HPV VLP, which typically
infects at a mucosal surface, is more immunogenic than bacteriophage VLPs. Lastly, we
displayed peptides from the HPV16 L2 coat protein on the bacteriophage VLP platform,
PP7. The resultant vaccine, PP7-HPV16L2, was administered intravaginally in mice to
determine whether a mucosally delivered vaccine could inhibit infection against a
pseudoviral challenge.

4.2 Introduction
Virus-like particles (VLPs) induce strong and long-lasting immune responses.
They can be used as stand-alone vaccines that target the viruses from which they are
derived and as scaffolds for presenting heterologous antigens. The clinically approved
VLP-based vaccines that target hepatitis B virus (HBV) and human papillomavirus
(HPV) are safe and effective, and represent the advancement of a new era in vaccine
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development. VLPs are also inherently biocompatible and self-assembling, and from a
manufacturing standpoint provide a facile and cost-effective solution to the engineering
concerns often posed by synthetic materials.
One reason for the VLPs’ success as a vaccine platform is its ability to evoke
strong antibody responses. These responses are generated by the VLPs’ structure: the
arrangement of coat proteins provides a dense, repetitive display of immunostimulatory
viral epitopes that B cells preferentially respond to. The multivalent nature of the particle
allows for cross-linking of the B cell receptors, which in turn sends strong signals
precipitating B cell migration, proliferation, and upregulation of surface molecules that
promote interaction with T helper cells. This cascade of events initiated by the unique
structure of the VLP allows for immunization at much lower concentrations, and without
the use of potentially harmful adjuvants, than non-particulate (such as subunit) vaccines.
Our lab has developed VLP-based vaccines that target a number of different
molecules derived from microbial and self-antigens. When given intramuscularly, these
vaccines consistently induce high-titer serum antibodies. As described elsewhere in this
thesis, we have been interested in using VLP-based vaccines to induce mucosal immune
responses, particularly for preventing infection by pathogens which are transmitted at
mucosal surfaces. Herein we characterize the development of a VLP-based, aerosolized
vaccine for the genital tract, and investigate the ability of that vaccine to prevent HPV
infection in a mouse model.
The most common sexually transmitted infections are caused by human
papillomaviruses. In the United States it is estimated that over 6 million new cases are
reported each year, and that over 20 million Americans are currently infected. There are
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over 100 different types of HPV, of which a subset of approximately 15-18 “high-risk”
types are known to cause cancer. Approximately 500,000 cases of cancer are caused by
HPV infection each year, the most common being cervical cancer (Parkin and Bray
2006). Of these cases of cervical cancer, it is estimated that 70% are caused by either
HPV16 or HPV18. Not surprisingly, the two HPV vaccines currently on the market
target both of these types. The Gardasil vaccine, developed by Merck and approved in
2006, targets 4 HPV subtypes: HPV16 and HPV18 (referenced above), and HPV types 6
and 11, which are associated with genital warts. The Cervarix vaccine, developed by
GlaxoSmithKline and approved in 2009, targets only HPV types 16 and 18.

Both

vaccines are composed of VLPs from the L1 major capsid protein of the HPV types
targeted. Consistent with the profile of VLP-based vaccines, Gardasil and Cervarix are
highly effective at preventing both infection and disease, induce long-lasting antibody
responses, and are incredibly safe (Koutsky, Ault et al. 2002).
The success of the current VLP-based HPV vaccines is largely due to their
targeting the major capsid protein L1, which is able to self assemble into a VLP and act
as a stand-alone vaccine. However one drawback of the L1-based vaccines is that L1 is
type-specific, in that the antibodies produced upon immunization are only able to provide
protection against the specific HPV type that was targeted.

For example, women

vaccinated with HPV16 L1 VLPs were protected against HPV16-related diseases, but not
against diseases caused by other HPV types (Koutsky, Ault et al. 2002; Mao, Koutsky et
al. 2006). However, HPV virions contain a second structural protein, the minor capsid
protein L2, which is highly conserved amongst HPV isolates. It has been hypothesized
that a vaccine targeting L2, in contrast to L1, could provide more comprehensive
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protection against multiple HPV types. In support of this hypothesis, it has been shown
that peptides from the N-terminal domain of L2 contain broadly cross-neutralizing
epitopes (Roden, Yutzy et al. 2000).
The specific reasons underlying L2 containing highly conserved, crossneutralizing epitopes are largely unknown. Although expression of L2 is not required for
the formation of VLPs, it is required for the formation of infectious virions. Indeed, there
is a positive correlation between viral infectivity and the L2 content of the virion (Buck,
Cheng et al. 2008). Yet in spite of L2s role in infectivity, neutralizing antibodies against
the protein are absent following both natural infection and immunization with VLPs.
Recent studies propose that the neutralizing epitopes are masked on the virion surface
until a conformational change exposes them following receptor binding to the virus.
Since the epitopes aren’t exposed until after HPV has bound its cellular receptor, there
would be little evolutionary pressure for L2 to undergo antigenic variation, thus
supporting the observation that the minor capsid protein is conserved across several HPV
type (Selinka, Giroglou et al. 2003; Richards, Lowy et al. 2006; Day, Gambhira et al.
2008).
Despite its potential to overcome the type-specific limitations imposed by L1VLP vaccines, an L2-based vaccine poses its own challenges. Immunization with L1/L2comprised VLPs fails to elicit immune responses against L2, but animal studies have
shown that immunization with bacterially-expressed L2 protein or L2-derived peptides is
successful at evoking a protective immune response (Lin, Borenstein et al. 1992;
Gambhira, Jagu et al. 2007; Alphs, Gambhira et al. 2008). However, unlike L1, L2 is
poorly immunogenic. The titers raised after vaccination with L2 are significantly lower
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than those elicited by L1 vaccines (Roden, Yutzy et al. 2000). Consequently, our lab has
sought to take advantage of our various VLP technologies and target L2 using VLP
platform technologies. We anticipate that display of L2 peptides on an appropriate VLP
platform will enhance the immunogenicity of L2.
Previously we used the bacteriophage Q! to display peptides derived from CCR5.
In this study, we used a recombinant VLP that had been previously developed by other
members of the laboratory (Caldeira Jdo, Medford et al.). In this vaccine, a broadly
cross-neutralizing epitope from L2 was inserted into a surface-exposed loop on the coat
protein of the single-stranded RNA bacteriophage PP7. Q! and PP7 are both members of
the family Leviviridae and their coat proteins have similar structures. Q! normally infects
E. coli whereas PP7 infects Pseudomonas aeruginosa. We have recently shown that the
PP7 coat protein is highly tolerant of peptide insertions, making it a useful platform for
genetic display of peptides. For example, intramuscular immunization with PP7 VLPs
displaying HPV16 L2 peptides induce high-titer antibodies against HPV16 L2 which can
protect from infection in a mouse pseudovirus challenge model (Caldeira Jdo, Medford et
al.).
The importance of mucosal immune responses was highlighted earlier in Chapter
3. To summarize, mucosal surfaces are often used by a wide variety of pathogens to gain
entry into hosts. One means an invading organism has of securing its survival is to take
advantage of the survival means of its host, in particular eating, breathing, and sexual
reproduction.

The immune system has responded and adapted by having a unique

immune environment for each of these receptive mucosal surfaces: the gastrointestinal,
respiratory, and genital mucosae, respectively. Because the environment of each of these
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mucosal compartments is distinct, it has been suggested that directly immunizing the
mucosal compartment targeted by a specific pathogen could result in the induction of
protective antibodies at the site of infection (Belyakov and Ahlers 2009). For example,
the inhaled FluMist vaccine and oral polio vaccines target the respiratory and
gastrointestinal tracts to successfully provide comprehensive mucosal and systemic
protection against the influenza and polioviruses (Herremans, Reimerink et al. 1999;
Haan, Verweij et al. 2001). However, apart from topical microbicides targeting bacterial
pathogens, the genital tract has remained largely under-utilized as a site for possible
vaccine delivery (Rusnati, Vicenzi et al. 2009).
The genital mucosa in particular is vulnerable to transmission of a host of
bacterial and viral pathogens, many of which can cause serious and incurable diseases.
For example, HPV, HIV and herpes simplex virus (HSV) are the most clinically relevant
of these sexually-transmitted viruses, and are associated with cervical cancer, AIDS, and
genital herpes, respectively.

Yet despite numerous efforts, only HPV has been

successfully targeted with a vaccine.

It is likely that a more comprehensive

understanding of the workings of the innate and adaptive immune system at the genital
mucosa, and their mechanisms of protection, is necessary for the rational design of other
vaccines against STIs.
We previously developed a bacteriophage VLP-based vaccine targeting the HIV
coreceptor CCR5 and showed that, following intramuscular administration, it induced
high-titer serum antibodies against CCR5 that can inhibit HIV/SIV infection. We have
also assessed the ability of this vaccine to induce mucosal immune responses, which is
desirable due to the number of pathogens transmitted at mucosal surfaces. In rats, both
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intramuscular and pulmonary immunization induced high titer IgG and IgA against the
vaccine in the serum, but only the aerosolized vaccine induced CCR5-specific IgA
locally in the lung and remotely in the genital tract (Hunter, Smyth et al. 2009).
Here, we present data comparing the magnitude of this "secondary" response in
the genital tract to the IgA response invoked following direct immunization of the genital
mucosa with different VLP platforms, including VLPs from a virus (human
papillomavirus) that normally infects in the genital tract, and VLPs of the bacteriophages
Q" and PP7. Taken together, our results provide a general method for inducing broad
systemic and mucosal antibody responses in discrete mucosal compartments using VLPbased immunogens.

4.3 Materials and Methods
4.3.1 Animal Immunizations
Groups of three to five Balb/c mice were immunized with Qß, PP7, or HPV16 L1
VLPs.

Mice given an intramuscular vaccine were immunized with 10!g of the

appropriate VLP preparation in incomplete Freund’s adjuvant, with the exception of mice
receiving the conjugated PP7 vaccine, which did not contain any adjuvant.

For

intravaginal immunizations, either via gel or aerosol (described below), 25 !g of VLPs
were applied without exogenous adjuvant. All mice were immunized on days 1 and 15;
the group immunized with HPV16 VLPs received a single boost on day 42, the group
immunized with PP7 received boosts on days 42 and 200 (Table 4.1). Serum samples
(approximately 0.1- 0.2 mL) and vaginal lavages (approximately 0.2 mL in PBS) were
collected prior to immunization, and every week until sacrifice. To minimize fluctuations
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in whole IgA levels, all mice received subcutaneous (sc) injections of Depo-Provera (3.0
mg in 0.1 mL) 4 days prior to immunization, and then every ten days until sacrifice, to
synchronize the estrous cycle. Synchronization was verified by microscopic examination
of cells obtained by vaginal lavage.

4.3.2 Preparation of immunogen for delivery
For each animal receiving the vaccine in gel form, 25 !g of VLPs were added to a
3% solution of carboxymethyl-cellulose (CMC) in distilled water. VLPs were highly
concentrated to ensure that the optimal viscosity was maintained.

Using a positive

displacement pipette (Gilson, Middleton, WI), 30 µl of the VLP-in-CMC gel was
delivered to the vaginal tract. For each animal receiving the aerosolized vaccine, 25 !g
of VLPs in PBS (in a volume not to exceed 50 µl) were loaded into a microsprayer highpressure syringe (Penn-Century, Wyndmoor, PA) and delivered to the vaginal tract.

4.3.3 Disruption of vaginal epithelia
Prior to genital immunization the vaginal epithelia was disrupted either by
mechanical or chemical abrasion.

Both methods of disruption were performed as

previously described (Roberts, Buck et al. 2007; Johnson, Kines et al. 2009). Briefly,
mechanical disruption was conducted immediately prior to immunization and performed
using a cytobrush (Cooper Surgical, Trumbull, CT). Chemical disruption was conducted
6 hours prior to immunization and performed by introducing 30 µl of a 4% nonoxynol-9
in 3% CMC solution into the genital tract.
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4.3.4 VLP preparations
A genetic insertion approach was used to display L2 epitopes on the surface of
PP7 VLPs, as described (Caldeira Jdo, Medford et al.). Briefly, the PP7 coat gene
sequence was mutated to introduce a KpnI restriction site so that insertion of foreign
sequences into the plasmid could be tolerated. PCR was used to insert a 15 amino acid L2
sequence into the PP7 coat. The ability of recombinant proteins to successfully assemble
in VLPs was assessed, and the PP7-HPV16L2 VLPs were purified. HPV16 L1-VLPs
were generously supplied by Michelle Ozbun (University of New Mexico).

4.3.5 Quantifying antibody responses
Sera and vaginal lavages were collected at the time points indicated, and all
samples analyzed by ELISA for antibodies specific to the appropriate VLP. ELISA
experiments were performed as previously described (Hunter, Smyth et al. 2008).
Specifically, Immulon II ELISA plates (Dynex Technologies, Chantilly, VA) were coated
overnight at 4°C with either 0.5 !g of HPV16, Q!, or PP7 VLPs per well. For analysis
of L2-specific antibody in sera from animals immunized with PP7-L2 VLPs, wells were
coated in three steps. First, 0.5 !g of streptavidin was applied per well for 2 h at room
temperature. After washing in PBS, 0.5 !g of the crosslinker SMPH was added to each
well. Lastly, after 2 h at room temperature, wells were washed again in PBS, 0.5 !g of
L2 peptide was added to each well, and plates were left overnight at 4°C. Following the
appropriate plate-coating procedure, all wells were blocked with 50 !L of PBS with 0.5%
milk (w/v) per well for 2 h at room temperature. An initial 1:40 dilution of serum was
serially diluted 4-fold and applied to wells for 2.5 h at room temperature. (All dilutions
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were done in 0.5% milk [w/v] in PBS unless otherwise noted.) Reactivity to the target
VLP was determined by using horseradish peroxidase (HRP)-labeled goat anti-mouse
IgG (Jackson Immunoresearch, Bar Harbor, ME) at a dilution of 1:4000 and incubated
for 1 h at room temperature. Upon development, the optical density at 405nm (OD405)
was determined using a Thermo Max microplate reader (ThermoLab Systems, Fisher
Scientific, Pittsburgh, PA).
considered positive.

Absorbancies greater than twice the background were

ELISAs for IgA were conducted as above, incorporating the

following changes: the blocking was performed with 0.5% BSA in PBS, the lavage
samples were applied directly to the wells at a single, 1:1 dilution, and presence of
antibodies was detected using HRP-labeled goat anti-mouse IgA (Open Biosystems,
Huntsville, AL).

4.3.6 HPV pseudovirus challenge
Following immunization, animals were genitally challenged with HPV16
pseudovirus encapsidating a luciferase reporter plasmid as previously described (Caldeira
Jdo, Medford et al. ; Cuburu, Kweon et al. 2009). Briefly, the vaginal epithelium was
chemically disrupted as described above. Six hours later, 8.0 µL of 3.7 X 108 IU/mL
HPV16 pseudovirus in 3% CMC was applied to the genital tract of each animal using a
positive displacement pipette.
Infection was detected as a bioluminescent signal using a live animal imager.
Forty-eight hours after pseudoviral challenge, anesthetized mice were given 20 µL of the
luciferace reporter substrate, XenoLight D-Luciferin Potassium Salt (Caliper Life
Sciences), and imaged with a Xenogen IVIS (Caliper Life Sciences). Images were taken

69

5 minutes after installation of luciferin at medium binning with a 5-minute exposure. The
average radiance per mouse was measured in photons/s/cm2/sr for a set region of equal
dimensions between mice.
Table 4.1: Experimental design for genital vaccines in mice
Inoculum

Disruption

Delivery & Dose

Method
Q!

Vaccination

Sacrificed

Schedule

@

N/A

Intramuscular + IFA (10 µg)

Weeks 0, 2

6 Weeks

Chemical

Gel (intravaginal) (25µg)

Weeks 0, 2

6 Weeks

Mechanical

Aerosol (intravaginal) (25µg)

Weeks 0, 2

6 Weeks

Chemical

Aerosol (intravaginal) (25µg)

Weeks 0, 2

6 Weeks

Chemical

Aerosol (intravaginal) (25µg)

Weeks 0, 2, 7

12 Weeks

N/A

Intramuscular (10 µg)

Weeks 0, 2, 8, 28

30

n=3
Q!
n=5
Q!
n=4
Q!
n=4
HPV16
n=5
PP7-16L2
n=4

Weeks

PP7-16L2

Chemical

Aerosol (intravaginal) (25µg)

Weeks 0, 2, 8, 28

30 Weeks

Chemical

Aerosol (intravaginal) (25µg)

Week 0

4 Weeks

n=5
HPV16-L1
n=5

4.4 Results
4.4.1 Direct immunization of the genital tract induces VLP-specific systemic IgG in
recipient mice
We had previously developed a VLP-based vaccine targeting the HIV coreceptor
CCR5. This vaccine was delivered via aerosol in rats, and was successful at inducing
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both systemic and mucosal immune responses against the target CCR5 peptide.

In

addition to finding specific antibody in the lung, low-titer antibodies were also found in
genital secretions. We asked how this secondary response in the genital tract following
delivery of a pulmonary vaccine would compare to the response elicited following direct
immunization of the genital tract. To this end, we assessed the responses to genital
vaccination with unconjugated VLPs using several different strategies.
Previous data from John Schiller’s group at the NIH suggested that vaccination
with HPV pseudovirions (for the purpose of inducing T cell responses) is enhanced by
disruption of the genital tract prior to immunization (Roberts, Buck et al. 2007; Iwasaki
2010). It is hypothesized that disruption of the vaginal epithelia prior to vaccination
allows for maximum uptake of the particles and exposure to resident antigen presenting
cells in the genital mucosa. We investigated the efficacy of two separate disruption
methods, chemical and mechanical disruption. Mechanical disruption was accomplished
by scraping the genital tract with a cytobrush immediately preceding immunization.
Chemical disruption was accomplished by applying a solution of 4% nonoxynol-9 in 3%
carboxymethyl cellulose (CMC) to the genital tract six hours prior to immunization.
Treatment with nonoxynol-9 has been shown to cause small abrasions in the genital tract;
these abrasions ultimately create a microenvironment that is more permissive to infection
than when left untreated (Roberts, Buck et al. 2007). In addition, we investigated two
vaccine application techniques. In the first, the vaccine was delivered to mice in a gel
format, with VLPs suspended in 3% CMC. In the second, VLPs were aerosolized and
delivered directly to the genital tract through a high-pressure syringe. In each case, mice
were immunized twice at a two-week interval with a dose of 25 µg of Q! VLPs without
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adjuvant. As a control, one group of mice received intramuscular immunizations, using
10 !g of Qß VLPs solubilized in incomplete Freund’s adjuvant. Sera were collected at
the time points indicated and serum antibody titers were determined by ELISA.

Figure 4.1: Aerosol immunization to the genital tract induces systemic antibodies

Figure 4.1. Serum IgG antibody titers following various administrations of a Q! VLP
vaccine delivered directly to the mouse genital tract. Mice were immunized on days 1
and 15 with Q! VLPs in gel (triangles) or aerosol (circles) format. Sera were collected at
the time points indicated and antibody titers determined by end-point dilution ELISA.
The aerosolized vaccine was administered following mechanical (green circles) or
chemical (blue circles) disruption of the vaginal epithelia. As a positive control, one
group was immunized intramuscularly (squares). The data shows the geometric mean
titer of each group of animals and error bars represent SEM. A) Kinetics of serum antiQ! IgG. Arrows indicate days of immunization. B) Comparison of serum anti-Q! IgG in
individual mice two weeks following second immunization. Bars represent the geometric
mean titer of each group.

72

As shown in Figure 4.1, the intramuscular route was the most successful at
inducing high-titer anti-Qß VLP IgG antibodies in the sera.

However, vaginal

immunization also resulted in systemic anti-Qß antibody responses. The peak antibody
titers in the best-responding vaginal immunization group were about 10-fold lower than
in the animals given vaccine via the intramuscular route. Aerosol administration of the
vaccine to the genital tract proved more effective than gel administration at inducing
antibodies in the sera, with chemical disruption of the vaginal epithelia producing more
uniformly higher titers than mechanical disruption. This trend is best illustrated in Figure
4.1 B, which shows IgG titers in individual animals at a single time point, one week
following the second immunization. Again, with the exception of one highly responsive
animal, aerosol immunizations preceded by mechanical disruption elicited titers two-fold
lower than those preceded by chemical disruption. Titers were sustained in all groups for
five weeks following the final immunization, though the group immunized with a VLPcontaining gel consistently had the lowest titers. The ability of the genital vaccines to
elicit a systemic response prompted us to determine whether they could also elicit a
robust mucosal immune response, and how that response compared to the one elicited by
the intramuscular vaccine.

4.4.2 Immunization of the mouse genital tract successfully induces local mucosal
antibodies
To assess the ability of the various genital vaccines to elicit a genital mucosal
antibody responses, we performed vaginal lavages at the time points indicated and
measured Qß-specific IgG or IgA in these secretions.
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Figure 4.2: Anti-Q! IgG and IgA levels in vaginal washes of immunized mice

Figure 4.2. Anti-Q! IgG and IgA levels in vaginal washes of immunized mice. Animals
were immunized via different routes as described above, and antibody levels determined
by ELISA. The data shows the geometric mean titer of each group of animals and error
bars represent SEM. The anti-Q! IgG (A) and IgA (B) responses are depicted kinetically
(left) and at a single time point, two weeks following the second immunization, in
individual mice (right).
As shown in Figure 4.2, intramuscular administration was able to elicit secreted IgG in
the genital tract (panel A), but we only detected IgA at a single timepoint (panel B).
Aerosol adminstration of the vaccine was markedly more successful at eliciting both IgG
and IgA than the gel, and chemical disruption of the vaginal epithelia prior to
immunization greatly improved antibody levels as compared to mechanical disruption.
Secreted IgA antibody levels diminished rapidly following the final intramuscular
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immunization, while they were sustained for up to 5 weeks in animals receiving the
aerosol vaccine. Based on these results, we concluded that the optimal protocol for
vaccine delivery to the genital tract was to chemically disrupt the vaginal epithelia prior
to immunization via an aerosol spray.

4.4.3 Magnitude of systemic immune response does not depend on type of VLP
platform
The next question we sought to address was whether the type of VLP used in the
vaccine influenced the magnitude of the immune response. We hypothesized that a VLP
derived from a virus that ordinarily infects at the genital mucosa may be preferentially
recognized and taken up by resident dendritic cells. As our previous results showed that
immunization with the Q! bacteriophage VLP was successful at inducing both mucosal
and systemic antibodies, we repeated these experiments (using only the aerosolized
vaccine) with HPV16 VLPs. HPV16 infects at the genital mucosa, is carcinogenic, and is
one of the subtypes currently targeted by the commercially available Gardasil vaccine.
We compare the mucosal immune response we observed upon immunization of the
genital tract with Q! bacteriophage VLP, which is a bacteriophage and does not infect
the mammalian genital tract, with a VLP type that is perhaps more readily recognizable
to the resident immune cells in the genital tract. On days 1 and 15, mice were immunized
intravaginally via aerosol with either 25 µg of HPV or Q! VLPs, following chemical
disruption of the vaginal epithelia. Sera were collected at the time points indicated and
analyzed by end-point dilution ELISA for specific IgG. As shown in Figure 4.3, both
VLP platforms were successful at eliciting high-titer antibodies in the serum, with mean
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titers peaking around 105. We followed animals immunized with HPV16 VLPs for two
months following the second vaccination. During this period geometric mean antibody
titers dropped approximately 10-fold.

Figure 4.3: Comparison of systemic immune responses following immunization with
Q! or HPV VLPs

Figure 4.3. Groups of four mice were immunized on days 1 and 15 (black arrows) via
aerosol to the genital tract. Mice received 25 µg of either Q! (&) or HPV16 (B) VLPs
six hours following chemical disruption of the vaginal epithelia. Sera were collected at
the time points indicated and analyzed for VLP-specific IgG via end-point dilution
ELISA. The bars show the geometric mean titer of each group of animals. Mice receiving
the HPV vaccine were given a third immunization on day 48 and the efficacy of this final
boost tested on day 73.
4.4.4 Mucosal immune responses in mice following aerosolized genital immunization
with two separate VLP platforms
To complete our analysis of the mucosal immune response following genital
immunization with either Q! or HPV16 VLPs, vaginal lavages were collected at the time
points indicated and analyzed at a 1:1 dilution by ELISA for either IgG or IgA specific
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antibodies against the appropriate VLP type. Both Q! and HPV16 VLP platforms were
successful at eliciting secreted IgG and IgA in the genital tract (Figure 4.4).
Figure 4.4: Comparison of local mucosal immune responses following immunization
with Q! or HPV VLPs

Figure 4.4. Groups of four to five mice were immunized on days 1 and 15 (arrows) via
aerosol to the genital tract. Mice received 25 µg of either Q! (&) or HPV16 (B) VLPs
six hours following chemical disruption of the vaginal epithelia. Vaginal lavage samples
were collected at the time points indicated and analyzed by ELISA for VLP-specific IgG
and IgA, and the OD determined. The bars represent the mean OD of each group of
animals. Mice receiving the HPV vaccine were given a third immunization on day 48 and
the efficacy of this final boost tested on day 73.
Levels of secreted IgG appeared only slightly higher in animals immunized with HPV16
VLPs, while IgG levels peaked sooner in the animals that received Q! VLPs.
Immunization with HPV16 VLPs elicited higher IgA levels than immunization with
Q! VLPs. In accordance with what was observed in the sera, animals that were
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immunized with HPV16 VLPs and observed over two months after the second
immunization were still producing and maintaining local IgG and IgA specific antibodies
in the genital tract throughout the course of study.

4.4.5 Ability of immunization with HPV16 VLP to confer protection against infection
Next, we assessed whether intravaginal immunization with HPV16 VLPs could
protect against HPV16 pseudovirus infection of the genital tract. Because we detected
both IgA and IgG responses after a single intravaginal vaccination, we asked whether a
single dose was sufficient to provide protection from challenge. A group of 5 mice was
given a single vaginal dose of HPV16 VLPs via the chemical abrasion, aerosol
immunization protocol. Vaginal lavages and sera were collected prior to application and
20 days following immunization. As shown in Figure 4.5, a single immunization was
sufficient for the induction of both systemic serum-associated antibodies in all 5 mice,
and mucosal antibodies in 4 out of 5 animals. Serum titers were several-fold lower than
the peak titers observed in prior groups receiving multiple immunizations.
Mice were challenged with HPV16 pseudovirus on day 24. A second group of
unimmunized mice were also challenged as positive controls.

Consistent with the

immune responses observed prior to challenge, 4 out of 5 animals were completely
protected against infection (Figure 4.6). Referencing back to Figure 4.5, the mouse that
was susceptible to infection was the same animal (#918) that failed to elicit mucosal
HPV-specific IgA and IgG antibodies in the genital tract. While this mouse also had
lower antibody titers in the sera, a second animal (#916) had equally low titers in the sera,
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yet displayed moderate levels of specific antibody in its vaginal washes, and was
protected against infection.
Figure 4.5: A single aerosol immunization of HPV VLPs via the genital tract is
sufficient for inducing systemic and mucosal antibodies

Figure 4.5. Mice (numbered 915-919) were given a single dose of aerosolized HPV16
VLPs via the genital tract. Sera and vaginal lavages were collected on days 0 and 20, and
analyzed by ELISA for IgG and IgA specific antibodies. For each animal, serum titers
are shown on the left (black); levels of IgG (red) and IgA (blue) from lavages are shown
on the right.
These data suggest that specific antibodies at the site of infection could alone be
sufficient for resisting infection. In addition, these data indicate that a single
immunization with an appropriate VLP platform is able to induce antibody levels in the
sera and mucosa that are ample enough to confer protection against viral challenge.
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Figure 4.6: Aerosol immunization of the genital tract with HPV16 VLP confers
protection from infection after a single immunization

Figure 4.6. Radiance per animal in unimmunized mice (B), and mice immunized via the
genital (A) routes. C) Average radiance per group. Data points represent individual
animals and data bars represent the mean.
4.4.6 Genital aerosol immunization with a recombinant VLP-based vaccine elicits
systemic and mucosal immune responses against both platform and target peptide
As described previously, VLPs can be used as stand-alone vaccines, but they can
also be used as platforms for displaying heterologous peptides in a highly immunogenic
multivalent format. To this end, we asked whether a recombinant VLP displaying HPVderived neutralizing epitope could also elicit an antibody response upon intravaginal
immunization.

We used recombinant VLPs in which a broadly neutralizing peptide
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derived from the HPV16 minor capsid protein, L2, was displayed on the surface of VLPs
from the RNA bacteriophage, PP7 (Caldeira Jdo, Medford et al.). We characterized the
magnitude of the mucosal and systemic immune response following aerosol
immunization of the genital tract using these PP7-16L2 VLPs.

Figure 4.7: Systemic immune responses against PP7 VLP and L2 target peptide
following aerosol immunization of the mouse genital tract

Figure 4.7. Mice were immunized either intramuscularly (“IM”, shown in squares) or
intravaginally via aerosol (“AVg”, shown in circles) with 25 µg of PP7-HPV16L2 VLPs.
Immunizations were carried out on weeks 0, 2 and 8; sera were collected and analyzed
via end-point dilution ELISA for (A) PP7- and (B) L2- specific IgG on weeks 0, 2, 3, 7
and 9, as indicated. The data shows the geometric mean titer of each group of animals
and error bars represent SEM.
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On weeks 0, 2, and 8 groups of mice were either immunized intramuscularly (IM)
or intravaginally via aerosol (AVg) with 10 or 25 µg of PP7-HPV16L2 VLPs,
respectively. Unlike previous IM immunizations, these were carried out in the absence of
adjuvant, in order to better compare the two vaccination strategies (as no adjuvant is
present in the aerosol preparation). Sera and vaginal lavage fluid were collected prior to
immunization and at the time points indicated, and analyzed for IgG and IgA antibodies
against both VLP platform and the target peptide. Both the IM and AVg approach
elicited high-titer IgG antibodies against PP7 in the sera (Figure 4.7 A), though titers
were approximately 10-fold higher in the IM immunized group. In IM immunized
animals, high-titer IgG against the displayed L2 peptide was achieved after a single
immunization, whereas animals immunized via AVg did not have significant anti-L2 IgG
until at least 2 weeks after their second immunization (Figure 4.7 B).
Antibody responses in the genital tract were consistent with what we observed
previously with Qß and HPV VLPs. The amount of vaginally secreted IgG was relatively
low in comparison to secreted IgA. The IM vaccine was more effective at eliciting
secreted IgG against the PP7 platform, and to a lesser extent the L2 target peptide, than
the AVg vaccine (Figure 4.8 A), although these responses were short lived. Secreted
IgA against PP7 and L2 was seen in the genital tract following both IM and AVg
administration of the vaccine, at levels higher than the observed IgG levels (Figure 4.8
B). There was no appreciable difference in the amount of IgA against PP7 or L2 at any
given time point between animals immunized IM or AVg, although IgA against PP7 was
more abundant than IgA against L2.
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Figure 4.8: Local mucosal immune responses against VLP platform and target
peptide following immunization of mouse genital tract
Figure 4.8.
Mice were
immunized as
described
above either
by IM
(squares) or
AVg (circles)
routes.
Vaginal
lavages were
obtained on
weeks 2, 3, 7,
9 and 29, and
analyzed by
ELISA for IgG
(A, C) and IgA
(B, D)
antibodies
against PP7
(A, B) and L2
(C, D). Bars
represent the
mean OD at
405.
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4.4.7 Genital aerosol immunization of the mouse genital tract with recombinant VLPs
confers protection from infection
In order to assess the long-term antibody responses in these mice, we followed
immunized animals for approximately 6 months after the initial immunization (Figure
4.8). We extended the study in the PP7-L2 group for approximately 5 more months
before challenge. Animals were given a final boost of HPV16L2-linked PP7 VLPs, for a
total of 4 immunizations, on day 195. On day 203, the IM and AVg groups were
challenged with HPV16 pseudovirus carrying a luciferase reporter. As a control, 3
unimmunized mice were also infected. Protection from infection was visualized as a
bioluminescent signal 48 hours post-infection using an IVIS live animal imager. The
number of infected cells is represented by the amount of radiance detected in a given area
per mouse. As shown in Figure 4.9, both AVag and IM immunization protected mice
from pseudovirus infection, although the protection was more dramatic in the mice
immunized through the intramuscular route. Immunization with aerosol via the genital
tract conferred only partial protection to the group, with two of the mice showing
complete protection (no signal), two showing no protection, and one mouse showing an
intermediate degree of protection. This was not surprising based on the pre-challenge
antibody titers observed in both groups, and it was anticipated that animals receiving the
genital vaccine would not be as protected from infection than those receiving the
intramuscular vaccine.
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Figure 4.9: Aerosol immunization of the genital tract with conjugated PP7 vaccine
confers only partial protection from infection
Figure
4.9.
A)
A
Radiance per animal
in mice immunized
via genital (top panel)
and
intramuscular
(bottom panel) routes.
B) Average radiance
per
group.
Data
points
represent
individual
animals
and
data
bars
represent
the
geometric mean.
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establish infections in the genital tract, it would also be greatly beneficial to have

85

neutralizing antibodies at this site to prevent infection.

The local production of

antibodies in the genital mucosa is mediated by resident plasma cells, which mostly
secrete IgA and can transport efficiently into the mucosal lumen (Holmgren and
Czerkinsky 2005). In order to guarantee stimulation of these IgA-producing plasma cells,
antigens need access to mucosa-associated lymphoid tissues (MALT). In terms of vaccine
design, this will probably best be accomplished via a mucosal administration of the target
antigens.
In contrast, existing HPV vaccines are parenterally administered, and likely
mediate protection through systemic IgG. Although systemic IgG is able to migrate to
the genital tract either through transudation or exudation at sites of microtrauma, IgG
titers in the cervicovaginal mucus are often 10-fold lower than in the serum, and continue
to diminish during ovulation (Nardelli-Haefliger, Lurati et al. 2005; Stanley, Lowy et al.
2006). Furthermore, traditional L2-based vaccines induce much lower neutralizing (and
particularly cross-neutralizing) antibody titers than L1-VLP-based vaccines such as
Cevarix and Gardasil, which regularly induce high-titer neutralizing antibodies.
Therefore, it is likely that the L2-VLP-based vaccines that we have developed will only
be successful if they induce similar high-titer neutralizing antibodies in the serum as L1VLP vaccines, or if they induce sustained local immune responses in the genital mucosa.
To this end, we proposed that a vaccine administered to the genital mucosa would
improve upon the IgG antibody levels seen following parenteral vaccination, as well as
incorporate IgA antibodies at the site of HPV infection.
The induction of genital immune responses is somewhat complicated however by
the compartmentalization of the mucosal immune system. Many studies have
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demonstrated to varied success the effectiveness of oral, intranasal and rectal vaccine
deliveries at inducing specific antibodies in genital secretions (Bergquist, Johansson et al.
1997; Kozlowski, Cu-Uvin et al. 1997; Johansson, Wassen et al. 2001; Kutteh, Kantele et
al. 2001), and our own studies correlate with the observation that presentation of antigen
to the lung, either via aerosol or intratracheal deposition, can especially enhance specific
antibodies in the genital tract (Balmelli, Demotz et al. 2002; Hunter, Smyth et al. 2009).
Yet limited evidence exists supporting intravaginal immunization for the induction of
local immunity in the genital tract (Wassen, Schon et al. 1996). This is mostly due to a
corresponding lack of reliable vaginal immunization protocols, although some success in
this regard has been recently reported using genetically engineered Salmonella
(Echchannaoui, Bianchi et al. 2008).
It was of interest, then, that a single mucosal administration of L1 VLPs was
sufficient to confer protection from genital challenge with a high-risk HPV. The ability
for a single, non-invasive immunization to confer protection may facilitate vaccine
implementation on a global scale. The success of the single immunization may in part be
due to the VLP platform used, as our studies suggest that HPV VLPs may be more
successful at generating high levels of antibody in the genital mucosa than the PP7 and
Q! bacteriophage VLPs platforms that we investigated and employed for antigenic
display of L2 peptides.
Here we have shown that a mucosal administration of aerosolized L2-VLPs is
effective at inducing IgA and IgG at the genital tract, but did not enhance the protection
from pseudoinfection provided by an identical intramuscular vaccine. Since protection
from vaginal challenge was not complete in those animals receiving only the genital
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vaccine, future studies should be undertaken to determine whether this was a failure of
uptake and presentation of the immunogen in the genital environment, or if it is due to the
overall weakness of the elicited mucosal immunity.

To distinguish between these

possibilities, it may also be necessary to determine whether our L2 vaccines can protect
against cutaneous challenge with HPV pseudovirions using a cutaneous challenge model
described by Roden and colleagues (Alphs, Gambhira et al. 2008).
The specific HPV peptide we chose to display is representative of an N-terminal
region on the HPV16 L2 protein that has previously been shown to contain broadly crossneutralizing epitopes. This epitope is also currently the target of an HPV neutralizing
monoclonal antibody, and when linked to a universal T helper epitope can elicit crossneutralizing antibodies against HPV (Gambhira, Karanam et al. 2007; Alphs, Gambhira
et al. 2008). One disadvantage of vaccination with a single L2 peptide is that it induces
protection that is greater for a homologous, rather than heterologous, HPV virus. For
example, Jagu et al showed that a concatenated multitype L2 fusion protein elicited more
broadly neutralizing antibodies than recombinant L2 derived from a single HPV type
(Jagu, Karanam et al. 2009). An advantage and future direction of our PP7 genetic
display system is that it provides for the rapid development of PP7 VLPs that can display
L2 peptides from a variety of HPV types.
A combination vaccine formulated to include additional HPV VLPs types is an
attractive possibility as it would probably be more effective at preventing cervical cancer.
For example, Merck has developed a nonavalent HPV vaccine that contains L1-VLPs
derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which is currently in
clinical trials. Assuming that it is effective, it is predicted that this vaccine will provide
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~90% protection (Munoz, Bosch et al. 2004). Although a nonavalent vaccine would be
highly beneficial, it is likely that such a vaccine would be very expensive. Indeed, the
current HPV vaccines are already amongst the most expensive vaccines in clinical use.
Moreover, because the vaccine is predicted to be ineffective against a small, but still
nonetheless significant, fraction of carcinogenic HPV types, costly cytological screening
of vaccinees will still be necessary. Together, these factors could present as barriers to
worldwide vaccine implementation, especially in the developing world where vaccines
are expected to have the most public health impact and where cervical cancer is the most
common of women. In support of a mucosally-administered vaccination protocol, which
could diminish the need for costly medical personnel and facilities, we can draw from the
hindered success of the hepatitis B vaccine in under-developed regions. The vaccine,
which requires several intramuscular injections, has been available for over 25 years, but
as of 2001 over 80 countries still lacked programs to enforce its successful
implementation (Kao and Chen 2002).
Immune responses to the same immunogen can vary dramatically depending on
the route of administration, even between different mucosal routes. This was previously
observed between the intranasal versus intratracheal routes of immunization, where it was
hypothesized that VLPs were presented to the immune system by DCs in the
tracheobronchial, but not nasal-associated, lymphoid tissues (Balmelli, Demotz et al.
2002). Likewise, the immune response to differing immunogens in the same mucosal
compartment can be variable. Herein we show that our intravaginal L1 VLP vaccine is
able to confer protection against intravaginal challenge following a single immunization,
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and that intravaginal immunizations with L2-displaying VLPs could also provide some
protection from challenge.
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Chapter 5: Breaking tolerance in rhesus macaques using a VLP-based
CCR5 mucosal vaccine delivered via aerosol to the genital tract
5.1 Introduction
For nearly three decades, the engineering of a successful HIV vaccine has
remained an elusive challenge. Sequence diversity and the virus’ immense capacity for
antigenic variation are two of several hindrances to successful activation of the cellular
and humoral arms of the immune system, both of which will likely be needed to
effectively offer prophylactic protection against infection. Because the CCR5 coreceptor
is a genetically stable self-protein, it is not subject to host immune pressures, unlike viral
targets, which can rapidly yield and select for mutated variants.

An extensive

background on CCR5, its role in virus acquisition, and its emergence as an HIV
therapeutic target is given in Chapter 2 of this thesis.
We have previously developed a papillomavirus (PV) VLP-based vaccine
targeting the N-terminal extracellular domain (EC1) of macaque CCR5 that induces antiCCR5 antibodies that bind to native CCR5 and block HIV infection in vitro (Chackerian,
Lowy et al. 1999). Moreover, prophylactic vaccination of macaques with this vaccine
reduced viral loads and time to clearance in pig-tailed macaques infected intravenously
with a CCR5-tropic simian-human immunodeficiency virus (SHIV) (Chackerian, Briglio
et al. 2004). In this latter study, it was also investigated whether the induction of
autoantibodies against CCR5 would contribute to or cause any deleterious effects. We
found that the antibodies elicited were not associated with any gross pathology or
peripheral blood abnormalities. More importantly, no reduction in T cells (which express
CCR5) was detected in the peripheral blood. This data suggests that strong immune
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responses against CCR5 may play a role in controlling viral replication. Furthermore, our
results correlated to a similar study by Misumi et al (Misumi, Nakayama et al. 2006). In
their study, macaques were immunized with a CCR5 ECL2 cyclic peptide (similar to that
used and discussed in Chapter 3 of this thesis) and then challenged with the same SHIV
isolate that we used. Again, vaccinated macaques had significantly lower viral loads
(~100-fold) than controls during the acute phase of SHIV infection.
Despite these successful findings, it is important to note some deficiencies to this
study. First, the antibody responses to CCR5 in the vaccinated macaques were variable,
underscoring the need to improve the vaccination regime so that high titer anti-CCR5
antibody responses can consistently be induced. Second, the SHIV challenge virus
SHIVSF162P3 that was selected replicated poorly in macaques and was eventually
eliminated by host immunity, making the role of anti-CCR5 autoantibodies in the control
of viral replication hard to assess. Third, it is highly possible that intravenous challenge
with SIV is an inappropriate model to demonstrate the effectiveness of a prophylactic
vaccine targeting CCR5, as transmission more commonly occurs via the anogenital
mucosa.
To address these concerns, we have incorporated several changes into our current
study. First, we believe that the variability observed in antibody responses could be due
in part to the VLP platform and display system. We have since shown that peptideconjugated Qß VLPs elicit stronger antibody responses than the papillomavirus VLPbased platform that was used previously (Chackerian, Rangel et al. 2006). To this end,
we continued developing a Qß-based vaccine, using the Qß-EC1 vaccine that
successfully evoked anti-CCR5 systemic and mucosal antibodies in rats as a template.
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(This particular vaccine study was presented in Chapter 3 of this thesis, and is
summarized briefly below.) Second, we chose to challenge with SIVmac251, a highly
pathogenic SIV, rather than SHIV, isolate. Third, we sought to make the challenge more
relevant by using an intravaginal immunization strategy, followed by intravaginal
challenge.
We believe that intravaginal inoculation with Qß-CCR5 vaccines will result in
strong genital mucosal antibody responses. The importance of inducing mucosal
immunity has come under increased scrutiny as a vital component of HIV-1 vaccine
design (Mazzoli, Trabattoni et al. 1997; Devito, Broliden et al. 2000). Specifically, the
genital mucosa plays a crucial role in the transmission of HIV, while the gastrointestinal
mucosa acts as an important site for early viral replication and amplification. Denise
Nardelli-Haefliger has shown that intravaginal application of human papillomavirus
(HPV) VLPs can induce strong anti-HPV antibody responses in mice (Echchannaoui,
Bianchi et al. 2008), and our colleagues in John Schiller’s laboratory have produced
similar results (Graham, Kines et al.). Furthermore, the use of an intravaginal challenge
mimics a common route of transmission and will therefore likely be more relevant for
assessing the candidate vaccines’ ability to prevent infection.
Presumably, antibodies against CCR5 would not be neutralizing, though it is
possible that they could block interactions between virus and the cells that are targeted
early in infection. For instance, Langerhans cells (LCs) can interact with HIV through a
variety of different surface receptors, and it has been shown that uptake of HIV by LCs
can be partially blocked by antibodies that bind CCR5 (Hladik, Sakchalathorn et al.
2007). Furthermore, low-level CCR5-reactive antibodies detected in the seronegative
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partners of HIV-infected individuals have been shown to possess virus inhibitory activity
in vitro, suggesting that anti-CCR5 antibodies may play a role in protection from natural
HIV infection (Lopalco, Barassi et al. 2000).
As was previously mentioned, we recently tested a bacteriophage VLP-based EC1
vaccine in rats. These results were presented in Chapter 3 of this thesis, but the results
can be summarized herein. The vaccine, which was delivered as an aerosol to the lung,
resulted in the induction of systemic IgG against CCR5 at similar levels as when rats
were immunized intramuscularly. The various pulmonary immunization protocols
explored resulted in ~10-fold higher IgA responses in the sera. Rats immunized solely
via the IM route had low IgG and undetectable IgA levels in bronchial and uterine
lavages and in feces. In contrast, rats immunized with the aerosolized vaccine elicited
mucosal IgA responses in the lung, feces, and uterus. IgG was only detected in the uterus
(Hunter, Smyth et al. 2009). Based on these results, we have shown that VLP-based
vaccines are compatible with mucosal (specifically, pulmonary) delivery and induce
high-titer systemic antibodies as well as local and systemic mucosal antibody responses.
Despite the success of the pulmonary vaccine, we felt confident that intravaginal
immunization would also elicit CCR5-specific antibodies in the genital tract based on our
results with the intravaginal HPV vaccine discussed in Chapter 4. As such, in this
chapter we present preliminary data from our study wherein we deliver an aerosolized
Q!-CCR5 vaccine to the genital tract of rhesus macaques, and determine its efficacy at
protecting against intravaginal viral challenge.
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5.2 Materials and Methods
5.2.1 VLP preparation
EC1 and ECL2 CCR5 peptides (representing extracellular domain 1 and the
second extracellular loop, respectively) were conjugated to Q! VLPs as previously
described (Hunter, Smyth et al. 2009).

Briefly, the 21 amino acid EC1 peptide,

representative of the N-terminal sequence (MDYQVSSPTYDIDYYTSEPC) of pig-tailed
macaque CCR5, was synthesized by American Peptide (Sunnyvale, CA). The ECL2
peptide (DRSQREGLHYTG) was synthesized by Celtek Peptides (Nashville, TN). Both
peptides have previously been shown in Figure 3.1. Each peptide was conjugated to the
Q! surface using the bifunctional chemial crosslinker, SMPH.
5.2.2 Macaque immunizations
Eighteen 4 to 10-year old rhesus macaques (Macaca mulatta) were obtained from
and housed at the California National Primate Research Center at the University of
California, Davis under the supervision of our collaborator, Dr. Koen Van Rompay. Two
groups of six macaques each were immunized 3 times at 4 week intervals with 25 µg of
Q! VLP alone (Q!) or a mixture of Q! -EC1 and Q! -ECL2 (Q!-EC1+ECL2) via the
intramuscular route (IM). A third group was given an IM prime (25 µg) of Q!EC1+ECL2; the remaining immunizations were given intravaginally via aerosol (AVg)
with 100 µg of the mixed VLPs. Serum samples were collected prior to and throughout
the course of immunization, as were cervical and vaginal secretions.

Cervical and

vaginal secretions were collected using a Weck-cell sponge as described (NardelliHaefliger, Wirthner et al. 2003). A detailed schedule of animal immunizations and
sample collection is shown in Table 5.1.
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5.2.3 Quantifying antibody responses
Serum specific for EC1- or ECL2- antibody was detected by ELISA. Immulon II
ELISA plates (Dynex Technologies, Chantilly, VA.) were coated with 0.5 µg of the
appropriate peptide, or Q! VLP, per well. Serum was serially diluted in 0.5% milk in
PBS.

Reactivity to target peptides was determined using a horseradish peroxidase-

labeled goat anti-monkey IgG (Fitzgerald Industries, Acton, MA) at a dilution of 1:4,000
as a secondary antibody. Upon development, the optical densities at 405 nm (OD405)
were read by a Thermo Max microplate reader (Molecular Devices Corp, Sunnyvale,
CA). OD405 values that were greater than twice the background were considered positive.
5.2.4 Avidity assay
The avidity of serum antibodies was determined by measuring the resistance of
antibody target complexes to a 5-minute 8M urea wash by ELISA as described
(Chackerian, Briglio et al. 2004) (Mazzoli, Trabattoni et al. 1997). Prior to urea wash,
duplicate wells were coated with the appropriate target peptide, blocked, and treated with
primary antibody (sera). Serum samples were loaded at the dilution that yielded the
antibody titer for each animal at room temperature for 2.5 hours. After washing 3 times
in PBS, wells were then treated with either PBS or urea for 5 minutes. Wells were then
washed again in PBS; subsequent steps are identical to those described in 5.3.3 above
following washing of the primary antibody. The avidity index value was calculated as
the ratio of the mean OD value of urea-treated wells to PBS, multiplied by 100.
5.2.5 Macaque challenge with SIV
The eighteen macaques were challenged with 105 50% tissue culture infectious
doses (TCID50) of SIVmac251 and again in the same manner 4 h later, as described
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(Stone, Keele et al.). Briefly, virus was introduced nontraumatically to the vaginal canal
using a needleless 1-mL tuberculin syringe. At challenge, macaques were transferred to
infectious animal housing, and followed for 12 months following infection. During this
period, blood samples were collected on weeks 1, 2, 4, 6, 8 and 10 following challenge,
and then every 4 weeks until necropsy.
5.2.6 Determination of viral load
Plasma-associated SIV RNA viral loads were determined using a real-time
quantitative reverse transcription PCR method as previously described (Chackerian,
Briglio et al. 2004) (Lifson, Rossio et al. 2001). Viral loads were transformed to the log
base 10 scale since data were approximately normal on that scale.

5.3 Results
5.3.1 Intravaginal immunization with VLP-CCR5 vaccine overcomes tolerance and
induces systemic antibodies in Rhesus macaques.
We expanded our previous Q!-EC1 vaccine to target two regions of CCR5 that
are involved in HIV binding: EC1 and ECL2, both of which have been discussed
previously. To review, our conjugation protocol resulted in individual Qß VLPs that are
coated with multiple copies (>100) of the two CCR5-derived peptides (Figure 3.1).
Although anti-ECL2 and anti-EC1 antibodies were somewhat weakly neutralizing
individually, in combination they displayed 50% inhibition of SIVmac251 infection at a
1:40 serum dilution in a single-cycle replication assay (Figure 3.4). While this might not
seem like a very high inhibition titer, any potential target cell will express multiple copies
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of CCR5, making inhibition of the receptor a more rigorous task than blocking the virus
itself.
We delivered this vaccine (designated Q!-EC1+ECL2) to 2 groups of 6 macaques
each. The first immunization was given to both groups via the intramuscular route. The
remaining 3 immunizations were given to one group (designated IM) via the
intramuscular route; the second group (designated AVg) was given the remaining
immunizations intravaginally, and in an aerosolized format. A third group of 6 macaques
(designated Q!) was immunized solely via the intramuscular route with unconjugated Q!
VLPs.

Table 5.1: Experimental Design for Genital Vaccines in Rhesus Macaques
(-1) wk
Procedure/Sampling (below)
Group 1 (IM Qß-CCR5)
1
IM immunization
1. Serum for ELISA
2. Blood/PBMCs for flow
cytometry (CD4, CCR5)
3. Cervical secretion sampling
(Weck Sponge)
4. SIVmac251 intravaginal
challenge (2x in 1 day)
Group 2 (IVag Qß-CCR5)
IM immunization
2
IVag immunization
1. Serum for ELISA
2. Blood/PBMCs for flow
cytometry (CD4, CCR5)
3. Cervical secretion sampling
(Weck Sponge)
4. SIVmac251 intravaginal
challenge (2x in 1 day)
Group 3 (IM Qß control)
IM immunization
1. Serum for ELISA
2. Blood/PBMCs for flow
cytometry (CD4, CCR5)
3. Cervical secretion sampling
(Weck Sponge)
4. SIVmac251 intravaginal
challenge (2x in 1 day)
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Figure 5.1. Intravaginal immunization with Q!-CCR5 overcomes tolerance and
induces systemic antibodies in Rhesus macaques.

Figure 5.1. Groups of 6 female Rhesus macaques were immunized with Q!-EC1+ECL2
on weeks 0, 4, and 8, and sera collected at the time points indicated for analysis by
ELISA for Q!-, EC1- and ECL2- specific IgG.
Animals were immunized
intramuscularly (“IM”, red) or received a single IM prime followed by boosts via aerosol
to the genital tract (“AVg”, blue). As a control, a third group was immunized IM with
unconjugated Q! VLPs (black). Bars represent the geometric mean titer.

To confirm that our Q! VLP-based vaccines could overcome tolerance and elicit
antibodies against macaque CCR5, we immunized Rhesus macaques on weeks 0, 4, 8 and
22 via the IM or AVg protocol with Q!-EC1+ECL2, or via IM with Q! alone. Sera were
collected at the time points indicated and described in Figure 5.1 and Table 5.1,
respectively.

Samples were analyzed by end-point dilution ELISA for specific IgG

against EC1 and ECL2 CCR5 peptides. Animals immunized both intramuscularly and
intravaginally with CCR5 peptides were able to elicit systemic antibodies against both the
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EC1 and ECL2 peptides. Titers against ECL2 were slightly higher (104-105) than titers
against EC1 (103-104) in both groups. There was no appreciable difference in titers
between the IM- and AVg- immunized animals (Figure 5.1).
Animals were given a final immunization on week 22 to test the ability of the
intravaginal vaccine to elicit a memory response. Serum samples were tested again by
ELISA on week 24, and the titer of each animal prior to challenge was determined.
These results, along with the approximate avidity of the serum antibodies, are shown in
Table 5.2. By week 22, titers in the AVg group were lower than those in the IM group.
Boosting brought up titers in only a fraction of the animals, with the IM group responding
better to the boost than the AVg group. However, all animals had high-avidity antibodies
(over 70%) against both EC1 and ECL2 peptides.

Table 5.2: Antibody titer and avidity at time of infection
Animal

IM
787
784
640
469
380
393
AVg
512
709
214
060
793
285

EC1 titer
wk 22

EC1 titer
wk 24

ECL2 titer
wk 22

ECL2 titer
wk 24

EC1 avidity
wk 24

ECL2 avidity
wk 24

40,960
2,560
40,960
10,240
640
640

163,840
655,360
655,360
163,840
2,560
10,240

655,360
163,840
163,840
655,360
10,240
10,240

163,840
655,360
655,360
655,360
163,840
163,840

High
High
High
High
High
High

High
High
High
High
High
High

10,240
640
640
2,560
640
40,960

2,560
2,560
640
2,560
160
10,240

10,240
10,240
10,240
40,960
2,560
163,840

163,840
40,960
10,240
10,240
2,560
163,840

High
High
High
High
High
High

High
High
High
High
High
High

High avidity, values > 50%; intermediate avidity, values > 30% but < 50%, low avidity,
values < 30%.
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5.4.2 Intravaginal immunization confers moderate protection against SIV challenge
in Rhesus macaques
An intravaginal challenge of the highly virulent SIV strain, mac251, was given to
all animals on week 26. Serum samples were collected weekly following challenge, and
viral load determined. As shown in Figure 5.2 A, 3 of the 12 animals immunized with
the CCR5 vaccine were substantially protected from infection, with viral loads that were
>10,000-fold lower than the mean of the Qß control group. Two of these animals were
from the group given the aerosolized intravaginal vaccine. The viral load of these 3
animals continued to decrease for 10 weeks following infection.

Upon log-

transformation of the viral load values, the AVg group appeared to have better protection
against infection than the IM group. Both groups had significantly lower viral loads than
control animals immunized with Q! alone (Figure 5.2 B).

5.4 Discussion
Vaccination against CCR5 represents an intriguing alternative strategy to inhibit
HIV infection, as conventional vaccines targeting HIV have failed. Here, in a macaque
model, we show that upon vaccination with phage VLPs conjugated with CCR5 peptides,
we were able to induce high titer antibody responses against those peptides, which
represent two regions of CCR5 important in virus entry. We attempted to increase
physiological relevance by using a highly-pathogenic SIV challenge virus and an
appropriate route of transmission. By delivering the vaccine intravaginally, we sought to
produce enhanced levels of local mucosal antibodies present at the time of intravaginal
SIV challenge. By comparing between the systemic and mucosal routes of vaccine
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administration, we attempt to shed light on the advantages, if any, that both approaches
provide.

Figure 5.2: Viral loads by individual and group following viral challenge

Figure 5.2. Following intravaginal challenge with SIVmac251, plasma was collected at
the time points indicated and analyzed by real-time quantitative reverse transcription
PCR for plasma-associated SIV RNA viral load. A) Viral loads of individual animals. B)
Viral loads of each group (left) and of Q!-CCR5 immunized versus placebo animals
(right). Viral loads were transformed to the log base 10 scale.
In this study, anti-CCR5 antibodies were induced upon intramuscular
immunization, as well as after an intramuscular prime followed by vaginal boosts.
Macaques were genitally challenged with a high dose (two doses of 105 TCID50) of the

102

pathogenic SIV strain mac251. Although vaccination did not prevent infection with SIV,
three of the twelve immunized animals had dramatically reduced viral loads. Two of the
three protected macaques were in the IM/AVg immunization group. By six weeks after
infection, SIV RNA was undetectable in plasma in these three macaques, and remains
undetectable as of our analysis ten weeks post infection.

The degree of protection did

not seem to correlate with anti-CCR5 antibody titers or antibody avidity; two of the three
protected animals had quite high anti-CCR5 serum-associated antibodies, but one had
lower titers. We are currently evaluating other correlates of protection – these will be
discussed in more detail in Chapter 6. Importantly, in the cases where vaccination was
able to provide protection, there are significant questions that will need to be addressed
regarding the long-term safety of vaccination against the self protein CCR5. These safety
concerns are also addressed below in Chapter 6.
In support of targeting CCR5, there are several other laboratories that have either
previously or are currently working towards the induction of anti-CCR5 antibodies. For
instance, Lucia Lopalco’s laboratory has developed a recombinant Flock House virus that
presents a peptide derived from CCR5 EC1 (Barassi, Soprana et al. 2005), and Tom
Lehner’s laboratory has developed a CCR5-HSP70 fusion protein immunogen (Bogers,
Bergmeier et al. 2004; Bogers, Bergmeier et al. 2004).

Three macaque challenge

experiments have also been reported following immunization with a CCR5 vaccine; our
own, the previously mentioned Misumi study (Misumi, Nakayama et al. 2006), and
studies by Wahren and colleagues, in which DNA vaccination with a construct containing
human CCR5 fused to tetanus toxoid was administered. The latter failed entirely to
protect macaques from SIVsm challenge (Zuber, Hinkula et al. 2000), while the two
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former studies reported only some degree of viral inhibition following challenge with a
SHIV isolate. It is important to point out that in these studies antibodies were generated
against human CCR5 in macaques. This is not an actual display of autoantibody
induction, and it is unclear whether the anti-human CCR5 antibodies cross-reacted with
macaque CCR5. In contrast, we have demonstrated previously and herein that our VLPbased system can overcome B cell tolerance and induce genuine autoantibodies against
macaque CCR5.
A successful vaccine will have to promote immune responses capable of
attenuating virus replication, immune disregulation, depletion of CD4+ T cells,
enteropathy and dissemination of virus from mucosal to lymphoid tissues in order to
provide sterilizing immunity. In recent years, it has become increasingly clear that in
order to accomplish this level of protection, an effective HIV vaccine must be capable of
eliciting local mucosal immune responses, both cellular (through CD8+ CTLs) and
humoral (specifically IgA antibodies), in addition to a systemic response.
The role of IgA antibodies as a sole defense is largely unclear, however there are
several studies supporting its importance in virus neutralization.

HIV-1 envelope-

specific mucosal IgA antibodies have been found to block transcytosis through epithelia
as well as virus entry in vitro. Furthermore, highly exposed seronegative women can
have secretory IgA in their cervicovaginal secretions, possibly contributing to the
rendering of a semi-protective state (Kaul, Plummer et al. 2001). It has been widely
proposed that an IgA-mediated mucosal immune response is best obtained through
mucosal, rather than parenteral immunization. Still, there appears to be no consensus
within the field whether a parenteral immunization route could generate sufficient
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mucosal immunity to confer protection, and it is likewise debatable whether
immunization via a mucosal route could generate the necessary local immunity necessary
for an effective HIV vaccine.
There are studies that have contradicted the need for mucosal immunization
entirely, particularly in the induction of T cell responses against HIV. Systemic (IM)
immunization alone was able to generate CD8+ CTL responses at multiple mucosal sites
in Rhesus macaques, indicating that mucosal immunization could be bypassed and longlived resident CD8+ T cell memory could be induced both systemically and at mucosal
effector sites (Kaufman, Liu et al. 2008). A second macaque study by Pal et al. showed
that systemic immunization had decreased the viral set point in blood and mucosal sites,
and protected against CD4+ T cell depletion (Pal, Venzon et al. 2006). It should be noted
however, that in both of these studies, a comparison was not made between the efficacy
of a mucosal immunization strategy versus a systemic one.
Comparisons between mucosal and systemic routes of vaccine administration
have however been made. For instance, numerous studies by Belyakov et al. have shown
that mucosal administration of a vaccine is more effective at eliciting high avidity
mucosal antibodies than when the same vaccine is delivered systemically.

More

importantly the mucosal vaccine, which was given intrarectally in macaques, was able to
better control viral load in gastrointestinal-associated lymphoid tissues (GALT), which
comprise a major reservoir for viral replication in early HIV-1 infection. The observed
generation of high-avidity CD8+ CTLs in the GALT inversely correlated with viral load
in the gut and correlated positively with the maintenance of CD4+ T help following
intrarectal challenge with SHIV (Belyakov, Hel et al. 2001; Belyakov, Isakov et al.
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2007).

Interestingly, these studies also support our observation that a heterologous

(prime-boost) immunization strategy is preferential when administering vaccines
mucosally; while our observations were restricted to humoral responses in the mucosa,
they have shown that a prime-boost regimen is also critical for the induction of high
levels of high-avidity CTL responses (Belyakov, Ahlers et al. 2008).
In conclusion, our study to date has shown that immunization with VLP-based
vaccines targeting CCR5 - including an intravaginal, aerosolized vaccine - are effective at
inducing serum-associated autoantibodies in Rhesus macaques. Some animals were able
to maintain undetectable to low viral loads upon challenge with a highly pathogenic SIV
strain. It is unlikely that natural transmission of the virus would initially contain such
high viral copies; ideally, further studies will determine the maximal dose that can be
tolerated and still result in protection. These results indicate that presence of CCR5specific antibodies may be sufficient for blocking infection, and that protection may be
conferred following heterologous (prime-boost) immunization via a mucosal route.
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Chapter 6: Discussion
6.1 Summary of Findings
The observation that many viral structural proteins have an intrinsic ability to selfassemble into virus-like particles (VLPs) has led to a new class of vaccines. VLPs have
been used as stand-alone vaccines targeting the viruses from which they are derived as
well as platforms for presenting heterologous antigens. This dissertation has described
the use of virus-like particles (VLPs) as flexible scaffolds for the display of heterologous
antigens to the immune system. Clinically approved VLP-based vaccines are safe,
effective, and comparatively easy to manufacture.

Their inherent biocompatibility

provides a facile and cost-effective solution to the engineering concerns often posed by
synthetic materials, and their ability to evoke strong antibody responses against even
poorly immunogenic targets makes them an attractive model for future vaccines targeting
antigens derived from both pathogens and self-molecules.
Our lab has developed a portfolio of display technologies that allow us to
deliberately modify VLPs so they can present essentially any epitope as a target antigen;
these particles have served as the basis for several vaccines targeting a variety of different
molecules derived from microbial and self-antigens. When given intramuscularly, these
vaccines consistently induce high-titer serum antibodies. In the previous chapters, we
have presented data showing that VLP-based vaccines are compatible with mucosal
delivery to both the genital and respiratory tracts. Vaccines targeting both viral and selfantigens were successful at inducing mucosal and systemic immune responses,
represented by the presence of IgG and IgA (when relevant) in the sera, and at local and
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remote mucosal sites. The induction of both mucosal and systemic immune responses
presents a particular advantage for preventing infection by pathogens transmitted at
mucosal surfaces. Indeed, we have herein shown that our L2 mucosal vaccines are
successful at preventing genital pseudoviral infection in a mouse model of HPV. As a
demonstration of the VLPs ability to evoke strong antibody responses against a self and
therefore poorly immunogenic molecule, we have also submitted data showing that
immunization of macaques with our CCR5 vaccine results in undetectable viral loads and
stable CD4 T cell counts in a subset of immunized animals following challenge with SIV.
In the remainder of this chapter, I will address specific concerns and limitations
surrounding my research, and identify strategies to address some of these concerns. I also
discuss the future directions of my research, and speculate on additional experimental
procedures that may strengthen this dissertation.

6.2 Limitations
There are several specific limitations to the various studies and experiments
described in this thesis. One common limitation throughout the work however is the use
of appropriate mucosal adjuvants. While we have proven that immunization with VLPs
is effective at generating an immune response without the use of adjuvants,
immunogenicity can still likely be enhanced with their use, which could result in
increased protection. Unfortunately, compared with adjuvants for parenteral vaccination,
mucosal adjuvants are much less effective. Also, less is known about the compatibility of
mucosal adjuvants with the deliveries we are proposing. For instance, our experiments
with inactivated cholera toxin B (CTB; Chapter 3) appeared to actually have decreased
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antibody responses. With very few exceptions, the group receiving this adjuvant had
lower IgG and IgA in the serum and at mucosal sites than the group without adjuvant.
Some adjuvants may be incompatible with nebulization, or may become separated from
the VLPs and taken up separately. From a technical standpoint, the microsprayers are
easily clogged, and any heterogeneity in inoculum could exacerbate this problem. One
possible way to correct for this would be to have our VLPs package their own adjuvants.
Examples of this were discussed in Chapter 1; to reiterate, CpG oligonucleotides can be
encapsidated, and if using an RNA-derived VLP platform, single- and double-stranded
RNA will intrinsically be present. While not strictly an example of an internal adjuvant,
a more stable option is also available when using VLPs derived from enveloped viruses.
For example, it was found that modification of SIV VLPs to incorporate CD40 ligand or
GPI-anchored GM-CSF into the lipid bilayer enhanced maturation and functional
activation of DCs and increased CD4+ and CD8+ T-cell responses to SIV Env protein
compared to VLP alone (Skountzou, Quan et al. 2007).
Generally, and somewhat obviously, this work would likely benefit the most from
a more comprehensive understanding of the cellular and molecular events that transpire
following vaccination. While it is generally accepted that the repetitive and dense nature
of antigenic display on the VLP surface is responsible for the particles’ supreme
immunogenicity, little is understood of the cellular interactions, trafficking, and
downstream events following uptake and presentation of the particles and their cargo,
particularly at mucosal sites.

This information could impact future vaccine design,

especially given the VLP’s amenability to manipulation. I interpret this gap in knowledge
more as a future direction for this work, rather than a limitation, and therefore propose
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additional experiments to pursue in Section 6.3. Below, I acknowledge model-specific
caveats and limitations to the CCR5 vaccines investigated in rats and macaques, and the
HPV vaccine work in mice.
6.2.1

Limitations Specific to Chapter 3: CCR5 Pulmonary Vaccine in Rats

From a technical standpoint, the potential magnitude of the immune response
garnered from the pulmonary vaccine was difficult to assess. The non-invasive chamber
allows for steady inspiration and expiration, which is not a realistic mimic of how the
vaccine would be administered in human subjects. Rather it is more likely that the
inoculum would be received in a single, rapid inhaled burst, similar to the inhaler used
for the FluMist vaccine. It can be assumed that there is substantial loss, or at least
incomplete lower airway deposition, with the current model. However, it is encouraging
that positive results were observed. Presumably, improvements to this model would only
enhance the magnitude of response. One way of anticipating how the response would be
affected is to use the microsprayer to deliver a single dose through the trachea of
anesthetized animals.
There are two possible ways to immunize intratracheally with the microsprayer.
The first is to essentially intubate the animal, accessing the lower airway through the
mouth. This is ideal, as repeated immunizations can be given. Unfortunately, as no one
in our laboratory or the Animal Resource Facility was experienced with small animal
intubations, and a lack of small-animal laryngoscopes made visualization of the airway
exceedingly difficult, I was not able to consistently ensure successful deposition of the
inoculum, which obviously generated erratic results. The second option we discussed
was to perform a tracheotomy, wherein a small incision is made directly in the trachea,

110

and the microsprayer inserted and deployed. The caveat to this approach is that animals
do not tolerate multiple tracheotomies, making successive immunizations an
impossibility. While it may have been valid to conduct single-immunization experiments
similar to those conducted in the HPV studies, as we were hoping to generate a
correlation between the immune response generated after multiple immunizations via the
exposure chamber, we decided against the invasive tracheotomy approach.
A second caveat to the rat studies is of course the lack of an appropriate challenge
model.

In many respects, this has been alleviated by our ongoing CCR5 vaccine

investigations in Rhesus macaques. Nonetheless, for the macaque studies, we adopted a
different vaccination route, making a true assessment of the efficacy of a pulmonary
vaccine at generating protective, receptor-blocking antibodies in the genital tract
unfeasible. For this reason, I am encouraged by the addition of the mouse model of
genital HPV infection to our studies. As is discussed in sections of 6.3 below, there are
many future directions we can undertake to fine-tune both the pulmonary and genital
VLP-based vaccines, and having a relevant animal model of infection on-site will allow
us to assess the success of these vaccine formulations.
6.2.2

Limitations Specific to Chapter 4: HPV Genital Vaccine in Mice

To best discuss the limitations involved in vaccine delivery to the genital tract,
further description of the immune environment at this site is required. As was mentioned
briefly in Chapter 4, there is a lack of reliable protocols for genital immunization. One
reason for this could be the variability in immune response elicited, which can differ
greatly depending on the target antigen, carrier, and form of inoculum (gel, aerosol,
liquid, etc.). Furthermore, individual mucosal compartments have unique compositions
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with regards to their immune environment; for example, the immune cell populations that
frequent the lung are different from those in the genital tract.
In general, mucosal surfaces can be divided into either type I or type II tissues.
Type I surfaces are composed of simple columnar epithelia characteristic of the gut and
lungs, and are likely the surfaces exposed to the inhaled vaccines we investigated. Type
II mucosal surfaces are found in the vagina, eyes and mouth, and are covered by a
protective stratified epithelial layer. The female genital tract is unique in that it is
comprised of both mucosal tissues; type I is found in the endocervix and uterus, while
type II is found at the ectocervix and vagina. In addition to histological differences, the
tissues are also distinguished by the presence (type I) or absence (type II) of IgA
transport mechanisms and mucosa-associated lymphoid tissues. As a result of the former,
there is also a major difference in the antibody isotype prevalent at each of these sites.
Secretory IgA is found at type I mucosae, while IgG is found at type II. (Iwasaki 2007;
Iwasaki 2010).
The immune response evoked following immunization with the gel-based vaccine
was somewhat surprising, as antibody titers were negligible, in contrast to the results
garnered by our collaborators in John Schiller’s laboratory (Graham, Kines et al.). It may
have been worthwhile to investigate this disparity to rule out the possibility of human
error. Another possible explanation for the observed low IgA response is that the gel
application was unable to reach the type I tissues of the upper genital tract, the
submucosa of which is constitutively filled with dendritic cells, macrophages and
memory lymphocytes, and which favors a secretory IgA response. In contrast, the type II
tissues found in the vagina and ectocervix contain a sparse network of DCs and
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macrophages, and rare lymphocytes (Wira, Fahey et al. 2005). Presumably, the smaller
droplet size and distributive force posited by the aerosolized vaccine would encourage
distribution in the upper genital tract.

A major limitation with the microsprayer

technology is the tendency for small volumes to incompletely nebulize; as volume is
reduced, the mist trends towards a fine spray. (Smaller volumes are necessary to avoid
loss as the volumetric capacities of the mouse genital tract are finite.) Furthermore, as
the immunization is essentially performed blindly, it is difficult to ascertain when/if the
inoculum is incompletely nebulized and to make notes of any resulting discrepancies
within an immunized group of animals.
From a translational standpoint, there is the problem of the vaccine requiring
epithelial disruption prior to administration. It would also certainly raise public concern
to continue to use nonoxynol-9, as several reports of its ability to permit sexually
transmitted infections have received media attention. Identification of an appropriate
adjuvant could sufficiently enhance uptake and negate the need for disruption.
Alternatively, it is possible that a prime-boost strategy for vaccine delivery could
ameliorate the need for disruption, as a baseline immunity would in theory already be
established. Lastly, it is possible that in sexually active subjects sufficient disruption
would be in place. Indeed, HIV-1 transmission is considerably increased by the presence
of pre-existing genital lesions (caused by other STIs) and microabrasions resulting from
sexual intercourse (Shattock and Moore 2003). Ultimately, I believe that the question of
epithelial disruption is premature, and that this limitation can be corrected following
further research and development.
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6.2.3

Limitations Specific to Chapter 5: CCR5 Genital Vaccine in Macaques

To date, the major limitation with the ongoing macaque studies is that the
animals, and therefore immunizations and sample collections, are all off-site. While this
doesn’t necessarily contribute to human error, it is difficult to account for unexpected
results. For example, much difficulty was experienced in the extraction of IgA from
Weck-Cell sponges, which were used as an alternative to a cervico-vaginal PBS wash. It
is doubtful that freezing, shipping, and thawing of the sponges affected the stability of the
contained antibodies, however the separate facilities ensure that samples will be limited,
prohibiting the opportunity to gather additional ones in the event of any error. Another
caveat to consider is the small cohort size, given the genetic diversity between animals.
Nonetheless, although statistical significance is difficult to determine, the varying
responses displayed are physiologically reflective, and can be helpful when considering
any products’ readiness for evaluation in clinical trials.

6.3 Overarching Future Directions
As our lab is illustrating with our work towards an L2-targeted HPV vaccine,
there are frequently improvements that can be made upon extant vaccines. Both our HIV
and HPV vaccine prototypes could undergo several phases of honing before an optimal
outcome is reached.

These improvements include but are not limited to boosting

immunogenicity, decreasing manufacturing cost, increasing the breadth of specificity,
making adjustments to particle size and chemistry, and investigating alternate routes of
administration. Some more specific experiments geared towards improving vaccine
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design of both the HPV and CCR5 VLP-based vaccines are discussed in sections 6.3.1
and 6.3.2 below.
As an overall theme however, I have grown increasingly interested in steering this
work towards more mechanistic studies. Specifically, the events that transpire between
immunization and antibody production: which cells encounter the VLPs, where VLPs
traffic, and possibly how other players participate in the initiation of the immune
response. There are several intriguing experiments that can be undertaken to this end.
The immense malleability of the VLP platform can allow for alterations to its physical
properties such that homing and biodistribution can be monitored, or even controlled. A
simple example of this would be delivery of a GFP- or other fluorophore-labelled
particle, followed by histology.

A more complex approach could involve the

incorporation of a highly sensitive high-contrast agent into the particles.

Folowing

administration, the quantity of particles able to reach relevant tissues, such as draining
lymph nodes or spleen, could be assessed by MRI (Song, Kohlmeir et al. 2008). Live
animal imaging for particle tracking is also possible using the IVIS (previously
described), or a Maestro EX (Cri) multispectral fluorescence imaging device, which is
able to obtain images from 550-900 nm in 10-nm-wavelengths. Additionally, surface
modifications can also be made to promote internalization and target specific cell
populations or receptors. For instance, chemokine ligands could be incorporated on the
particle surface and used to bind cognate receptors on cell subsets of interest. The use of
fluorophore-coupled particles would make the monitoring of particle uptake by these cell
populations possible via flow cytometry. In addition to providing a general method for
studying recruitment pathways, a similar tactic has been exploited as an approach for
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vaccine development. First, a single immunization via a conventional parenteral route
acts as a “prime” to trigger all arms of the adaptive immune response. Following this,
selective lymphocyte populations (CD4+ T cells, CD8+ T cells, or B cells) can be
reoriented to a desired site using a second signal, or “pull”. For example, CXCL-9 has
been used to drive CTLs into vaginal tissues following intramuscular immunization
(Nakanishi, Lu et al. 2009).
6.3.1

Future directions pertaining to HPV vaccine

The current VLP-based HPV vaccines, in addition to including viral epitopes,
stimulate innate immune recognition in dendritic cells (DCs), and it is likely that this
stimulation contributes to the success of these vaccines. During natural infection, HPV
molecules engage multiple mechanisms to prevent the initiation of a robust immune
response. Depletion of LCs by the E6 protein, downregulation of MHC I by E5, and
blockade of Type I IFN signaling by E7 are examples of the several viral evasion
mechanisms in play that ensure a poor host immune response. Again, I am interested in
delving more into the interactions between VLPs and resident antigen presenting cells,
and the specific mechanisms by which VLPs are able to initiate an immune response in
spite of the several tactics employed by an invading virus. In the case of HPV infection,
these cellular interactions will most likely involve DCs.
Cross-presentation of HPV antigens is likely to be carried out by uninfected DCs,
as the antigen presentation capacities of these cells are not affected by the
aforementioned evasion mechanisms.

Presumably DC activation takes place upon

recognition of virus-infected cells by an endosomal pattern recognition receptor (PRR).
Because HPV occurs only in the type II epithelial layer, LCs in the epithelial layer and
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possibly submucosal DCs extending their dendrites towards the epithelial layer are the
cells most likely to participate in this process. Similar to what I discussed and proposed
in the above section, I think much can be learned of cell to cell interactions through
fluorescent labeling of VLPs, and either tissue or live animal imaging. For instance,
future studies of the innate recognition system for intact HPV virions, identification of
the pattern recognition receptors (PRR) involved in VLP recognition and the nature of
pathogen-associated molecular patterns (PAMPs) being recognized would provide further
insights into the basic biology of PV detection, and could have an immense impact on
vaccine development.
With regards to vaccine design, if the genital immunizations fail to impart more
complete protection upon genital challenge, I think it would be worthwhile to return to
immunization via the pulmonary route. This would be especially advantageous as our
previous work in rats was not able to incorporate relevant viral challenges. The mouse
model for HPV infection would allow us to assess how well the inhaled vaccine performs
at conferring protection from pseudoviral infection. Also, unlike the viral challenges
undertaken in macaques, these animals would be on-site, providing a more fiscally
prudent and ethically sound arena with which to fine-tune the pulmonary vaccine.
Furthermore, any insights gained from the proposed VLP trafficking and uptake
investigations could be translated into vaccine modifications and efficiently assessed for
improved efficacy.
Future directions towards the development of an L2-targeted VLP HPV vaccine
are also underway on a much larger scale. We are currently collaborating with Drs.
Michelle Ozbun and Cosette Wheeler on a project focused on basic and applied HPV
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research. In addition to our research, the facility’s broader projects include (but are
certainly not limited to) the development and evaluation of a macaque model of genital
PV infection, and population-based studies to elucidate the effectiveness of current
vaccines and the influence of vaccination on the prevalence of HPV genotypes.
6.3.2

Future directions pertaining to CCR5 vaccine

As the study with the CCR5 vaccine in macaques is ongoing, there are several
experiments that are yet to be done. Many of these address the physiological effect of
inducing autoantibodies against CCR5, how the virus may respond to these antibodies,
and the correlation, if any, between antibody titers and clinical outcome. Regarding
investigating the effects of autoantibodies against CCR5, we have collected blood
samples throughout the course of study to examine whether anti-CCR5 antibodies would
lead to the downregulation of CCR5 expression in vivo. At monthly intervals, macaque
PBMCs will be isolated and CCR5 expression levels determined by flow cytometry. A
Quantibrite-based assay can be used to measure absolute numbers of CCR5 on cells.
Additional samples of macaque sera were also collected once a month following the final
immunization. IgG will be purified from this sera using a Protein A/G column and tested
for its ability to block SIV infection using the ptCCR5-MAGI assay described in Chapter
3 of this thesis.
As was previously mentioned, the presence of anti-CCR5 antibodies could block
SIV infection in macaques and essentially lead to three different outcomes: 1) protection,
2) sustained reduction of viral loads, or 3) temporary reduction in viral loads. In the
cases of outcomes 2 & 3, we will examine the effects of vaccination on the phenotype of
the virus that persists in the vaccinated animals. This understanding will be especially
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important in the case of outcome #3, with animals whose viral loads rebound, although as
of yet the observed trend is that protected animals have been maintaining low viral loads
with no indication towards a rebound. To determine phenotype of the persistent virus,
PBMCs will be taken from vaccinated and control macaques approximately one year
after SIV challenge. DNA will be isolated from PBMCs by standard methods. In order
to isolate virus from infected animals, PBMCs will be co-cultured with an equal number
of activated macaque PBMCs isolated from naïve rhesus macaques.

Virus will be

cultured for up to 4 weeks, and virus production assessed weekly by an antigen capture
assay measuring p27 gag in the supernatant. In the event we experience difficulty
expanding the virus via this method, we could alternatively co-culture infected PBMCs
with the CEMx174 cell line, as SIV envelope genotypes have been shown to be stable
upon co-culture with this cell line (Rudensey, Papenhausen et al. 1993). After the period
of expansion, supernatant will be collected. Virus derived from co-cultures will be tested
for coreceptor usage using a panel of coreceptor expressing cell lines (the GHOST cell
lines) obtained from the AIDS repository.
Virus will also be tested for sensitivity to anti-CCR5 mouse IgG, using the
ptCCR5-MAGI assay previously described. If a shift in coreceptor usage or resistance to
anti-CCR5 IgG is detected, we will PCR amplify and sequence envelope clones from
infected PBMC DNA, using standard methods (Chackerian, Morton et al. 1994).
Because shifts in coreceptor usage typically map to the genetic changes within the V3
region of envelope (Kuhmann, Pugach et al. 2004), we will sequence this region from 4-6
envelope clones from each macaque.

Together, these analyses should give us an

assessment of the genotypic and phenotypic responses of SIV to CCR5 vaccination.
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To assess clinical outcome, all animals will be observed until September of 2011,
12 months following the challenge, unless illness progresses to an unmanageable state
and euthanization is required. During this 12-month period, blood will continue to be
collected every 4 weeks and analyzed to determine viral load. As a secondary measure of
efficacy, we will also examine how the level of anti-CCR5 antibodies affects clinical
outcome. This relationship may prove difficult to assess, as it is rarely straightforward.
For instance, CD4+ T cells are predicted to be a major sink for cell-associated CCR5
antibodies. A loss of these cells during disease progression might therefore tend to
increase serum CCR5 antibodies. This could result in an inverse correlation between
CCR5 titers and CD4 counts.
A second confounding factor is that the total amount of CCR5 autoantibodies
induced is the sum of free serum and cell-associated antibodies. Antibodies that have low
avidity may preferentially reside in the serum compartment, and are least likely to protect
against infection. Protection is conferred by cell-associated antibodies, however to date
only the serum antibodies have been measured. To correct for this, experiments are
currently underway to determine levels of cell-associated CCR5-specific antibodies.

6.4 Regarding the importance of CCR5 antibodies at the genital tract
Several modes of entry have been suggested for HIV-1, including transcytosis
through a microfold cell (M cell), uptake by DCs, and entry through microabrasions in
the epithelial layer. Early in infection, additional cell types may be targeted, such as
resident activated memory T cells or Langerhans cells (LCs), which have been proposed
to facilitate HIV infection by capturing virus, migrating to regional lymph nodes, and
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then transferring virions to susceptible T cells. It is undetermined how successfully antiCCR5 antibodies, rather than virus-neutralizing antibodies, in the genital tract at time of
virus transmission could inhibit infection. In addition to DCs expressing CCR5,
Langerhans cells in the foreskin and CD4+ T cells seem to predominantly express CCR5,
providing a selective advantage for R5-tropic virus transmission (Margolis and Shattock
2006). As is suggested by individuals heterologous for the #32 mutation, a reduction,
rather than complete eradication, of surface CCR5 is sufficient to significantly reduce the
incidence of infection. Presumably, anti-CCR5 antibodies would act by blocking the
receptor or reducing its surface expression through internalization or sequestration; the
most critical factor is whether these antibodies could be long-lasting and present at the
time of exposure.

It may also be relevant to investigate an oral mucosal route of

vaccination using our CCR5 vaccines, given the role of the gastrointestinal tract in the
gross depletion of CCR5-expressing T cells during early HIV-1 infection. Lastly, it is
also unclear whether the majority of virus during early infection would be cell-associated
or free virions. While anti-CCR5 antibodies would only affect cell-associated virus, it is
likely that IgA mucosal antibodies would play a more important role in protective
immunity against free virus.

6.5 Safety Concerns Regarding Inducing an Immune Response Against CCR5
As our vaccine proposes to induce an antibody response against a self-protein, we
have anticipated that safety concerns will likely arise. In response, several points can be
raised in defense of a vaccine targeting CCR5. First, we have learned much about the
effects of the CCR5-#32 allele in human populations, and can apply that knowledge to
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anticipate possible effects of anti-CCR5 therapy. To this date the only suggestion that the
CCR5-#32 mutation may be associated with enhanced susceptibility to disease is in
individuals infected with two flaviviruses, West Nile Virus and tickborne encephalitis
virus (Glass, McDermott et al. 2006; Kindberg, Mickiene et al. 2008). Obviously, we
cannot extend observations made in knockout individuals to predict the consequences of
functional inactivation of CCR5 in normal individuals. Therefore a second and better
gauge for weighing the potential side effects posed by a CCR5 vaccine may be PRO 140,
a humanized CCR5 monoclonal antibody (mAb) for the treatment of HIV infection
(Progenics Inc.). PRO 140 is currently in clinical development, and has been reported to
exhibit favorable safety and efficacy data (~1.5 log mean reduction in viral loads at the
highest dose) in a phase 2 clinical trial (http://www.medicalnewstoday.com/articles/138779.php).
If a favorable safety profile emerges from larger phase 3 clinical trials, it would support
the possibility that a CCR5 autoantibody inducing vaccine could also be safely delivered.
While not related to safety, concerns over manufacturing costs are always raised when
approaching vaccine implementation.

In this case, cost of delivery favors a CCR5

therapeutic vaccine over CCR5 mAb therapy for use in the developing world, as
treatment with currently licensed mAbs costs more than $10,000 per year.

6.6 Conclusions
The recent success of clinically-approved VLP-based vaccines for Hepatitis B Virus and
Human Papillomavirus highlight that effective vaccines against sexually-transmitted
viruses are possible. The challenges for further success lie in the diversity of these
viruses; each STV will likely require a specific type of effector immunity to confer host
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protection.

For instance, for viruses that undergo rapid mutation, such as HIV-1,

antibodies will need to either broadly neutralize highly-conserved epitopes, or be targeted
to unconventional or alternative non-viral antigens to elicit the CD4+ and CD8+ T cell
and B cell responses necessary to curtail virus propagation.

The investigation of

strategies to involve the mucosal, in addition to the systemic, immune system in the
initiation of an immune response may be critical to the development of future vaccines
against a number of pathogens infecting at mucosal sites. Our research contributes to this
objective by showing that VLP-based vaccines targeting both self and viral antigens are
compatible with a number of mucosal-delivery applications, and are able to generate
protective immune responses at mucosal sites in animal models. The relatively noninvasive approaches described herein may facilitate economic vaccine deployment to the
developing countries where they are needed most, and minimize risks associated with
parenteral vaccines.
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